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1CHAPTERGeneral introduction
Elevated blood pressure during pregnancy can be subdivided into a form that an-
tedates pregnancy (chronic hypertension), a form that is confined to the period of
pregnancy and also complicated by proteinuria (preeclampsia), and a form in
which preeclampsia is superimposed on chronic hypertension. In preeclampsia the
vascular pathology is characterized by the combination of a generalized vasospasm,
enhanced thrombocyte aggregation and increased capillary permeability. These
symptoms are consistent with endothelial dysfunction and may interfere with or-
gan perfusion.
High blood pressure complicates almost 10% of all pregnancies '. It is, together
with obstetric hemorrhage, embolism and obstetric infection, the most common
cause of maternal mortality. In a period of four years (1987-1990), it was directly
responsible for 256 deaths on a total of 1453 maternal deaths in the United States,
corresponding with 1.6 maternal deaths per 100,000 live births .^ The working
group on maternal mortality of the Dutch Society of Obstetrics and Gynecology
reported 13 cases on a total of 66 maternal deaths in the Netherlands between
1988 and 1992, corresponding with 1.7 maternal deaths per 100,000 live births ^.
Maternal hypertension is also an important cause of perinatal morbidity and mor-
tality, as it predisposes for intra-uterine growth retardation and iatrogenic preterm
delivery performed on fetal or maternal indication.
Since the cause of preeclampsia is unknown, current treatment modalities are lim-
ited to symptomatic relief and optimal timing of delivery. Unfortunately, only the
latter, rather aggressive treatment option can be seen as definitive, for it removes
the diseased tissue: the placenta. A more causal management and treatment of
preeclampsia will not be achieved until the pathogenesis of the disorder is fully dis-
closed 1
In their studies Duvekot et al. '•" provided evidence for a defective maternal he-
modynamic adaptation in the first weeks of pregnancy preceding defective fetal
growth later on in pregnancy. Their observations in the latter group of women
suggested volume maladaptation in the first eight weeks of pregnancy in this par-
ticular group. It is conceivable that this seeming persistence of a state of vascular
underfill in early pregnancy triggers or at least contributes to the development of
intra-uterine growth retardation (IUGR) and preeclampsia in advanced preg-
nancy. The relative hypovolemia may lead to a raise in both sympathetic tone and
RAA-system activity in the post-implantation period, causing a redistribution of
the cardiac output away from the invading trophoblast. The latter can be expected
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to interfere with placentation. Poor placentation is generally considered to play a
central role in the pathogenesis of preeclampsia.
Central and renal hemodynamic changes in the menstrual cycle resemble those in
early pregnancy. Firstly, the mean arterial pressure in the luteal phase (LP) has de-
creased relative to the follicular phase (FP) ^. This decrease is accompanied by a fall
in osmotic thresholds for thirst and vasopressin release ", suggesting that these
phenomena may represent compensations in response to a primary decrease in
vascular tone. Secondly, most reports on this topic provide experimental evidence
for a luteal rise in glomerular filtration rate (GFR) ' ' ^ . This luteal rise in GFR is
probably flow-induced as there is some evidence for a concomitant increase in ef-
fective renal plasma flow (ERPF) " . However, the use of suboptimal markers for
GFR and ERPF together with a lack of standardization of sodium intake through-
out the menstrual cycle do not allow firm conclusions on this matter.
Thirdly and lastly, an increased activity of the RAA-system during the LP as com-
pared to the FP has been demonstrated " " " .
ti The combination of the above mentioned hemodynamic maladaptation in early
o pregnancy in case of IUGR and the resemblance of the hemodynamic changes in
£ the LP, relative to the FP, with those in early normal pregnancy led us to the fol-
£ lowing hypothesis:
/'« «ir/y/wgnanfy zV wj/rrorft
To test this hypothesis, we studied central and renal hemodynamic changes dur-
ing the menstrual cycle in healthy subjects using the hemodynamic adaptations as
observed in early pregnancy as a reference. In an initial pilot-study (Chapter 3) we
addressed the question whether there were indeed indirect signs for a generalized
vascular relaxation in the LP. Afterwards, we focused on changes in overall periph-
eral, renal, and forearm vascular resistances during ovulatory (Chapter 5) and ano-
vulatory (Chapter 6) menstrual cycles, in subjects on a standardized salt-intake.
During the measurement sessions we also studied possible changes in body fluid
volume (Chapter 4 and 6).
In addition, we investigated whether renal hemodynamics and plasma volume in
the LP of the menstrual cycle differ between parous subjects with or without
preeclampsia in their recent history (Chapter 7). Finally, we compared cyclic
changes in renal hemodynamics and plasma volume in these two categories of
subjects to determine whether ex-preeclamptics elicit an abnormal hemodynamic
cyclicity during the menstrual cycle (Chapter 8).
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Pathogenesis of preeclampsia:
a comprehensive model
E. van Beek, MD, L.L.H. Peeters, MD, PhD
Departments of Obstetrics and Gynecology,
University Hospital Maastricht, Maastricht, The Netherlands
; 53/233-23P
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ABSTRACT
The objective of this review was to provide a comprehensive and practical concept
on the pathogenesis of preeclampsia on the basis of the currently available scien-
tific evidence.
A MEDLINE search was performed of English language articles published be-
tween 1966 and 1997, supplemented with references cited in relevant research ar-
ticles.
Using our data sources we developed a scheme describing the sequence of events
between implantation and the time of manifest clinical disease characterized by
generalized endothelial cell dysfunction. A yet unidentified toxic circulating factor
released by the ischemic placenta, is held responsible for the impaired endothelial
cell function. Particularly, epidemiological studies point to a concept in which im-
mune maladaptation to the fetal allograft plays a key role in causing defective pla-
•2 centation leading to placental ischemia. The incidence of preeclampsia in sisters
E and daughters of women who have had preeclampsia is raised. Disease states with
| vascular involvement, like chronic hypertension and diabetes mellites, are associ-
°- ated with an increased risk for preeclampsia. Recently subclinical abnormalities in
S hemostasis, metabolism and volume homeostasis have been described in patients
| with a history of preeclampsia.
o" Placental ischemia secondary to defective placentation, a prerequisite for the de-
2 velopment of preeclampsia, has a multifactorial origin consisting of three major
* components: immune maladaptation, genetic predisposition and vascular medi-
§ ated factors. Probably, a summation of these factors will determine whether a
S pregnant woman is to develop the syndrome. The recently described subclinical
abnormalities in hemostasis, metabolism and vascular function in patients with a
history of preeclampsia might give the clinician the opportunity to reduce the re-
currence risk by pharmacotherapeutic intervention.
High blood pressure complicates almost 10 percent of all pregnancies '. It is, to-
gether with obstetric hemorrhage, embolism and obstetric infection, the most
common cause of maternal mortality. In a period of 4 years (1987-1990), it was
directly responsible for 256 deaths of a total of 1,453 maternal deaths in the
United States, corresponding with 1.6 maternal deaths per 100,000 live births .^
The working group on maternal mortality of the Dutch Society of Obstetrics and
Gynecology reported 13 cases of a total of 66 maternal deaths in the Netherlands
between 1988 and 1992, corresponding with 1.7 maternal deaths per 100,000 live
births '.Maternal hypertension is also an important cause of perinatal morbidity
and mortality, because it predisposes for intrauterine growth retardation and ia-
trogenic preterm delivery performed for fetal or maternal indications. Classifica-
tions of hypertensive disorders of pregnancy have been made by the World Health
14
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Table 1. Classification of hypertensive disorders of pregnancy.
Chron/c hypertens/on Known hypertension before pregnancy or rise in blood
pressure to > 140/90 mm Hg before 20 weeks amenorrhea.
Preec/amps/a/ec/amps/a Increased blood pressure accompanied by proteinuria (>300
mg/24 hour specimen), edema or both, occurring almost
exclusively after 20 weeks amenorrhea. Rise in blood
pressure by > 15 mm Hg diastolic, by > 30 mm Hg systolic
from measurement in early pregnancy or to > 140/90 in late
pregnancy if prior blood pressure is not known. Eclampsia is
the occurrence of seizures in a patient with preeclampsia.
Preec/amps/a superimposed
on chron/c Ziype/tens/on The combination of chronic hypertension and preeclampsia.
Trans/enr /iypertens/bn Rise in blood pressure as for preeclampsia without
proteinuria.
Organization (WHO), American College of Obstetrics and Gynecology
(ACOG), the International Society for the Study of Hypertension (ISSH) and the
U.S. National Institutes of Health Working Group on Hypertension in Preg-
nancy '. A description of the latter classification, which is widely accepted for its
clarity and simplicity, is outlined in Table 1. The most important consideration in
the classification of elevated blood pressure during pregnancy is the subdivision of
hypertension into a form that antedates pregnancy (chronic hypertension) and a
form that is confined to the period of pregnancy (preeclampsia). In the latter con-
dition the vascular pathology is characterized by the combination of a generalized
vasospasm, enhanced thrombocyte aggregation and increased capillary permeabil-
ity all of which have a negative impact on organ perfusion. The objective of this re-
view is to provide a practical and comprehensive model about the pathogenesis of
preeclampsia on the basis of currently available scientific evidence.
Endothelial cell dysfunction, the final common pathway
Many observations point to a central role of the endothelial cells in the pathogene-
sis of pre-eclampsia. First, there is morphologic evidence of endothelial cell injury
in the kidney known as glomerular endotheliosis " \ Shanklin et al. described ul-
trastructural endothelial injury in the placental bed and adjacent uterine vessels '^.
Second, functional derangements or biochemical evidence of damaged endothe-
lial cells have been described in preeclamptics: high circulating concentrations of
the von Willebrand factor '®'", endothelin 20.21^  ^ d ^ g cellular epitope of fi-
bronectin 22-24 Disturbances of the total plasminogen activator (tPA) and plasmi-
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nogen activator/inhibitor balance and the prostacyclin (PG^/thromboxane
(TXA2) balance are in favor of an increased tendency of thrombocytes to aggregate
and of vessels to constrict 25.26 These morphologic and functional changes of the
endothelial cells can be held directly responsible for triggering the clinical syn-
drome: arterial vasospasm, increased thrombocyte aggregation and increased cap-
illary permeability leading to hypertension, proteinuria, edema and sometimes
thrombocytopenia and hypoperfusion of organs.
Placental ischemia, the starting point
Based on many reports, the placenta, like the endothelium, plays a key role in the
pathogenesis of preeclampsia. Preeclampsia is an exclusive disease of pregnancy
that implies that it will resolve within 48 hours after delivery of the placenta. The
occurrence of preeclampsia in molar pregnancies supports the central role of the
placenta in the development of the syndrome ^ . Similarly, the occurrence of
•3 preeclampsia in abdominal pregnancies emphasizes the irrelevance of the decidua
£ in the pathogenesis of the disease ^ ' ^ .
t The following inferences support the concept that reduced placental perfusion hasto play a major role in pregnancies eventually complicated by preeclampsia. In a
normal pregnancy trophoblastic invasion is associated with striking changes in the
arteries supplying the intervillous space. The diameter of spiral arteries proximal
to the trumpet-shape outlet increases four- to six fold relative to that in nonpreg-
nant women (Fig. 1). The endothelium is replaced by trophoblast, and the inter-
nal elastic lamina is replaced by trophoblast and an amorphous matrix that
consists predominantly of fibrin deposits. These vascular changes extend from the
intervillous space up to the inner third of the myometrium 30.31 gy contrast, these
changes develop defectively in preeclamptic women and are also limited to the de-
cidual portion of the spiral arteries, with myometrial segments maintaining their
smooth muscle layer ^ (Fig. 1). These vessels have diameters that are only about
40 percent of those of the vessels of normal pregnancies ^ . Some spiral arteries in
decidua and the myometrium are occluded by fibrinoid material and surrounded
by foam cells. These features, are known as atherosis, and resemble those seen with
allograft rejection **. One consequence of the abnormal invasion of the spiral ar-
teries is a deficient uteroplacental circulation already at the end of the first trimes-
ter. The latter is supported by histopathologic findings of villi in preeclamptic
patients that consistently show a pattern of abnormalities characteristic for villous
growth in a low oxygen environment " . Chronic reduction of the aortic pressure
in rhesus monkeys can produce a syndrome resembling preeclampsia. This obser-
vation supports the hypothesis of a reduced perfusion of the implantation site al-
ready at the time of the initial trophoblast invasion -^ '.
The pathway culminating in placental ischemia holds the key to our understand-
ing of the pathogenesis of preeclampsia. Research today focuses on both this so-
16
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Figure 1. Diagram illustrating defective placentation. The left side of the diagram shows normal
adaptation of spiral arteries to pregnancy, whereas the right side depicts this process in
preeclamptics. Vil = intervillous space; sp = spiral artery; dec = decidua; rad = radial artery; arc =
arcuate artery; myom = myometrium.
called "defective placentation" and the missing link between placental ischemia
and generalized endotheiial dysfunction. The available epidemiological evidence
supports the view that the origin of this placentation defect is multifactorial, con-
sisting of three major components: immune maladaptation, genetic predisposi-
tion and vascular-mediated factors. Probably, a summation of these factors will
decide whether a pregnant woman is destined to develop the syndrome and its se-
verity.
Immune maladaptation
The concept of an abnormal maternal immune response to the trophoblast is
largely based on epidemiological studies. The risk of developing preeclampsia is
reduced in subsequent pregnancies compared with the first provided conception is
achieved by the same partner 37.38 ^ spontaneous abortion or blood transfusion is
associated with a lower risk of preeclampsia in a subsequent pregnancy 39,40
Other studies associate preeclampsia with the frequency and duration of maternal
exposure to semen . There is an inverse correlation between the duration of co-
habitation and the risk of developing preeclampsia ^ . Women using barrier meth-
ods of contraception have twice the likelihood of developing preeclampsia than
women using oral contraceptives or an IUCD ^ Finally, the incidence of
preeclampsia in pregnancies from donor inseminations is higher than expected ^ .
All these observations support an as yet undefined key role of the immune re-
sponse of the mother to antigens on the trophoblast in the development of
preeclampsia. It is tempting to speculate that the normal tolerance process of the
fetal allograft develops abnormally. Many studies have been designed to compare
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humeral and cellular immune functions in pregnancies complicated by
preeclampsia and normal pregnancies to find evidence for the impaired tolerance
hypothesis. The majority of reports do not demonstrate modifications in the con-
centration of IgM, IgA, IgG and IgD levels during normal or hypertensive preg-
nancies ^ . Some studies showed abnormal maternal sensitization with an
increased reactivity against placental antigens, paternal cells ^ and fetal cells ^ .
However, other studies demonstrated a reduced or normal proliferative re-
sponse of maternal lymphocytes in the presence of paternal lymphocytes. Unfor-
tunately, most of the results are in conflict with each other primarily, because of
the presently limited understanding of normal fetal allograft tolerance. Further-
more, the relationship between the outcome of in-vitro tests and the in-vivo re-
sponses is still poorly defined ^ . Powerful protective mechanisms are likely to be
activated to ensure the avoidance of graft rejection during pregnancy. The classical
HLA class la antigens, expressed on all nucleated cells, normally serve as recogni-
tion structures for rejecting genetically foreign tissue by cytotoxic T-lymphocytes.
Trophoblast cells are a notable exception. In these cells a class Ib HLA gene,
HLA-G, is expressed-^. The unique tissue distribution of HLA-G suggests that this
molecule plays a key role in the induction of maternal tolerance in pregnancy ^' '^.
An alternative hypothesis suggests that maternal production of blocking antibod-
ies plays an important role in the survival of the conceptus as an allograft ^ . De-
creased formation of these protective blocking antibodies could lead to a maternal
immune response directed against endovascular and interstitial trophoblast inva-
sion. Placental ischemia and activation of polynuclear neutrophils seem to be the
most severe consequence of this abnormal maternal immune response, which trig-
gers the chain of events with ultimate endpoint systemic endothelial damage/dys-
function and associated symptomatology of preeclampsia.
Genetic predisposition
In a prospective study in 1961, Chesley and co-workers were the first to describe
the familial factor of preeclampsia ^ . They reported on a markedly increased inci-
dence of preeclampsia and eclampsia in the first pregnancies of sisters (37 percent)
and daughters (26 percent), of 187 eclamptic women relative to the incidence in
the general population (8 percent) '4.55 Studies addressing the mode of transmis-
sion are hampered by the slow reproductive cycle in the human and the confine-
ment of the phenorype to pregnancy. Several hypotheses concerning the
inheritance of a gene that regulates the susceptibility to preeclampsia have been
proposed, all of them attempting to reconcile epidemiological data with a model
of transmission. Sutherland et al. ^ and Chesley et al. ^ proposed a simple mater-
nal recessive transmission with an estimated gene frequency of 0.237 (Scottish
population) and 0.253 (New Jersey population), respectively. Both studies ruled
out a significant genetic contribution by the fetus because they found a population
18
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incidence of preeclampsia for in-laws. For an Icelandic population, Arngrimsson
et al. '* described two mathematical models with an equal fit: a recessive mode of
transmission with a causal gene present in 31 percent of women and an autosomal
dominant mode of transmission with a gene frequency of 0.14 and a penetration
of 48 percent.
Evidence favoring that a contribution of the fetal genotype to the occurrence of
preeclampsia has led to the assumption of a combined mode of transmission. For
example, Cooper et al. ^ reported a raised incidence of eclampsia in women born
of eclamptic pregnancy (37 percent) as compared with women having a sister or
brother born of eclamptic pregnancy (14 percent). Liston et al. ^" studied six sim-
ple Mendelian models of inheritance by comparing theoretical expectations and
data from published family studies. They concluded that only one of the genetic
models considered was consistent with the observed incidence values for relatives
of index cases, namely the one in which both mother (a,a) and fetus (a,a) must ex-
press the same recessive gene to confer susceptibility. Another argument against a
simple Mendelian genetic model acting only in the mother is provided by twin
studies. Thornton et al. "' could only demonstrate the occurrence of preeclampsia
in one of the identical twins, never in both twins. They concluded that preeclamp-
sia is not a maternal autosomal recessive condition. They were not able to exclude
the possibility of a maternal dominant inheritance with incomplete penetrance
(upper limit 31 percent)
Linkage of preeclampsia to a susceptibility gene could be of value in the early pre-
diction of preeclampsia. Hayward and co-workers ^ searched for this linkage in
two generation families in which preeclampsia was rigorously defined. Unfortu-
nately, they did not find evidence for linkage of preeclampsia to the HLA region or
to several genes implicated in the pathogenesis of hypertension.
Vascular-mediated factors
Diseases, clinical or subclinical, which interfere with the function of endothelial
cells, are known to increase the risk of preeclampsia. These conditions are able to
act at three levels in the cascade leading to preeclampsia: defective placentation,
placental ischemia and endothelial cell dysfunction (Fig. 2). Table 2 lists these risk
factors together with their risk ratio ^ . The common factor is their interference
with the condition/function of the maternal vasculature. Some of them, such as
diabetes mellitus and chronic hypertension, are well-known risk factors. Recently
Dekker et al. ^  reported that more than 50 percent of the patients with a history of
severe early-onset preeclampsia showed hidden abnormalities in metabolism
and/or hemostasis. These abnormalities consisted of protein S deficiency, acti-
vated protein C resistance, the presence of anticardiolipin antibodies in the pe-
ripheral blood, and hyperhomocystinemia. All of these conditions facilitate the
activation of the clotting cascade. Prepregnant identification of these abnormali-
19
Defective
placentation
-Immune maladaptation
-Genetic predisposition
I-Vascular mediated factors
Figure 2. Postulated pathogenesis of preeclampsia.
Endothelial
cell
dysfunction
Arterial vasospasm
Thrombocyte aggregation f
•Capillary permeability f
I
-Hypertension
-Proteinuria, edema
-Thrombocytopenia
-Hypoperfusion of organs
Table 2. Vascular mediated factors involved in the pathogenesis of preeclampsia (risk ratio)
C/wwwc /7yperfens/bn 10:1
D/abefes me///fus 2:1
/Auto/mmune rf/sorders, e.g. Sif, anf/p/)osp/>o//p/d syndrome 10:1
Cbron/c rena/ /nsuffic/ency (serum crear/n/ne > 7.4 mg/d() 20:1
5ubc//n/ca/ abnorma//t/es /n mefabofem and/or hemosfas/s
g/V>ng nse to rnrombopn/7/a (see text) increased
ties in patients with a history of preeclampsia offers the possibility of anticipating
an increased recurrence risk.
In our follow-up study (at least five months postpartum), we found approximately
a 10 percent lower plasma volume in patients with a history of preeclampsia as
compared with controls ^ . Also in a normotensive subgroup the subnormal
plasma volume was paralleled by a lower plasma concentration of atrial natriuretic
peptide (ANP) and higher plasma concentrations of aldosterone as compared with
controls. The effective renal plasma flow (ERPF) was lower and the filtration frac-
tion higher in ex-preeclamptics as compared with controls. Both the observed dif-
ferences in hormone levels and the lower renal blood flow supported the existence
of a hypovolemic state in ex-preeclamptics as compared with controls. These ob-
servations support some yet unidentified vascular-mediated risk factor to be in-
20
Chapter 2 • Pathogenesis of preeclampsia
volved in the pathogenesis of preeclampsia, which has as a common effect a
constricted plasma volume compartment. Obviously, a prospective study is
needed to determine whether this interrelation is causal or coincidental.
The missing link
It is an attractive hypothesis that preeclamptic women have a circulating factor re-
leased by the ischemic placenta, that interferes with endothelial function, giving
rise to vasoconstriction, enhanced capillary permeability and activation of the
clotting cascade. Both Rodger et al. ^ and Tsukimori et al. ^ demonstrated that
the sera from preeclamptic women damage human endothelial cells in-vitro. By
measuring the release of radiolabeled chromium from the cells into the culture
medium, Tsukimori et al. ^ described a selective affinity of this serum factor to
endothelial cells, and not to vascular smooth muscle cells or fibroblasts. Smirason
and co-workers ^ could only demonstrate a toxic effect of plasma and not serum,
to endothelial cells of women with preeclampsia as compared to controls. The ex-
planation for this discrepancy lies probably in the fact that they assessed a different
aspect of endothelial cell function namely spontaneous proliferation by measuring
tritiated thymidine incorporation.
What is behind this so-called "factor X"? ^" A current concept is the formation of
oxygen free radicals caused by immune maladaptation, and subsequent activation
of (decidual) lymphoid cells, and placental ischemia. These extremely reactive
oxygen species are assumed to play an important role in many physiologic reac-
tions. However, when their production exceeds the neutralization capacity of free
radical scavengers, a condition of imbalance is created which favors the formation
of lipid peroxides from unsaturated fatty acids. Oxygen free radicals as well as lipid
peroxides are toxic for endothelial cells ^'. Together with oxygen free radicals and
cytotoxic cytokines, proteases such as elastase are released by activated neutrophils.
These proteases are able to destroy the integrity of endothelial cells, vascular base-
ment membrane and subendothelial matrix. Plasma neutrophil elastase is elevated
in preeclamptic patients when compared to normotensive controls, and correlates
with the elevated levels of the von Willebrand factor ^ .
Alternatively, changes in lipid metabolism in preeclamptic women could represent
"factor X". Lorentzen and co-workers ^ found that sera from women with
preeclampsia induced accumulation of triglycerides in endothelial cells, which in-
terfered with endothelial cell function as indicated by reduced prostacyclin release.
The same group demonstrated that both an increased ratio of free fatty acids to al-
bumin and an enhanced lipolytic activity of sera from women with preeclampsia
resulted in a higher endothelial uptake of free fatty acids, which are further esteri-
fied into triglycerides ^ .
Smarason and co-workers ^ proposed that a likely candidate for "factor X" is syn-
cytiotrophoblast, which is shed from the microvillous membrane into the mater-
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nal circulation. They found that syncytiotrophoblast microvillous (STBM)
membrane suppressed the growth of cultured human derived umbilical endothe-
lial cells (HDUEC) and disrupted the cell monolayer. Unfortunately, there was no
difference in activity between the STBM membrane preparations from
preeclamptic and normal placentas. Their group already showed that trophoblast
deportation was markedly increased in preeclampsia *^\ Next, they hypothesized a
quantitative rather than a qualitative difference, suggesting an increased release of
active substance in preeclamptic women.
CONCLUSIONS
Pregnancy complicated by preeclampsia can be a life-threatening event for the fe-
tus and the mother. Central to the pathogenesis of preeclampsia are placental
~ ischemia secondary to an initial defective placentation, and generalized endothe-
£ lial cell dysfunction at the end of the cascade leading to preeclampsia. The link be-
S tween these two, the toxic circulating "factor X", and the multifactorial origin of
£ this defective placentation are subject to current research. Impaired development
.£ of immunologic tolerance may lead to an activated immune system during tro-
| phoblast invasion and subsequent defective placentation. Genetic predisposition,
£ the possession of a susceptibility gene, and maternal vascular pathology could be
£ modulating factors in this process. The recent finding of latent abnormalities in
^ hemostasis and metabolism (giving rise to thrombophilia), and volume homeosta-
S sis in patients with a history of preeclampsia is suggestive for an important role of
5 these vascular-mediated factors in the pathogenesis of preeclampsia. Prepregnant
identification of these abnormalities in patients with a history of preeclampsia may
enable the clinician to foresee the recurrence risk and allow him to institute pre-
ventive measures before pregnancy or in the subdinical phase of the disease.
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SUMMARY
/. The objective of this study was to investigate whether the lineal phase of the
menstrual cycle differs from the follicular phase by the development of a state of
general vascular relaxation.
2. Once in the follicular and once in the luteal phase of the menstrual cycle, we
measured by non-invasive techniques: arterial blood pressure (by finger blood
pressure measurements), vascular tone (by pulse-wave velocity and plethysmogra-
phy), blood flow to skin (by laser-Doppler), blood flow to forearm (by plethys-
mography) and blood flow to kidneys (by para-aminohippurate clearance), and
"g, the glomerular filtration rate (by inulin clearance). The data points obtained in the
•5 luteal phase were compared with those in the follicular phase by non-parametric
K tests.
I 3. Arterial blood pressure, vascular tone and the blood flows to the forearm and
1: kidneys were comparable in the two phases of the menstrual cycle. In contrast, the
.0 blood flow to the skin was consistently lower, and the glomerular filtration rate
™ higher in the luteal phase of the menstrual cycle.
•g 4 The results of the present study do not support our hypothesis of a general vas-
al cular relaxation in the luteal phase of the menstrual cycle. The lower skin flow in
•J5 the luteal phase may be an adaptation needed to ensure the higher core tempera-
's, ture of 0.3-0.5 °C in the luteal phase. The higher glomerular filtration rate was in
£ most cases paralleled by a higher renal blood flow in the luteal phase. This suggests
* that the higher glomerular filtration rate is secondary to a selective vasorelaxation
S of the afferent renal arterioles.
INTRODUCTION
Several studies have shown that systemic hemodynamics and volume homeostasis
in women are related to the menstrual cycle. The mean arterial blood pressure
(MAP) was found to be lower ,^ and the plasma renin activity and creatinine clear-
ance higher in the luteal phase (LP) than in the follicular phase (FP) of the men-
strual cycle '" ' '5. In addition, the osmotic thresholds for thirst and vasopressin
release were reported to have decreased in the LP ". From a theoretical point of
view, all these changes could be viewed as compensatory mechanisms triggered by
a decline in filling pressure of the arterial tree ^ . Such a state may develop in a
healthy person, when the arterial/arteriolar tone slackens.
The steroid environment in the LP differs from that in the FP primarily by the
presence of progesterone in the former. Both progesterone ^ ' ^ and 17(3-estradiol
"" can independently induce vascular relaxation. However, these data have been
obtained either from animal studies ^ or in vitro using human placental arteries
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and veins ^ . Moreover, it is incorrect simply to extrapolate these results to the
complex endocrine environment of the LP.
Our objective was to investigate in vivo, whether the hormonal environment in
the LP induces a general vascular relaxation in humans. To this end we measured
the differences between the LP and FP in venous and arterial tone and in the blood
flow to three vascular beds: skin, forearm and kidney. We also determined the
glomerular filtration rate (GFR) and filtration fraction.
SUBJECTS AND METHODS
Experiments were performed in nine healthy volunteers (< 40 years of age) with a
regular menstrual cycle of 28 ± 2 days and evidence of ovulation, indicated by a
mid-luteal serum progesterone concentration > 5 ng/ml *'. All participants gave
written informed consent and the study was approved by the hospital's medical
ethics committee. Measurements were taken once in the FP, between the 4th and
10th days, and once in the LP, between the 20th and 24th days of cycle. The sub-
jects' characteristics are listed in Table 1. The two measurements were taken ran-
domly. This implied that four subjects started the measurements in the FP
whereas five subjects started in the LP.
Methods
All investigations were performed in a temperature-controlled room (24-25 °C.)
and at the same time of day. The subjects were asked not to smoke, not to drink
beverages containing caffeine or alcohol on die day of measurements and not to
eat during the last three hours before the measurements. We took precautions to
minimize external disturbances during the measurements. The measurements
were started after an acclimatization period of at least 30 minutes; they were per-
formed with the subject in supine position and the arm under investigation at
heart level. Before the acclimatization period a 20 gauge catheter was inserted into
a vein of the left forearm for infusion of para-aminohippurate sodium (PAH) and
inulin (see renal hemodynamics).
The arterial wall distensibility was assessed by measuring the pulse-wave velocity.
The pulse-wave velocity is based on the time needed for an arterial pulse to travel
over a standardized distance in a given artery (transit time, ms). The transit time
provides information on the average elastic state of the artery over that particular
distance ^ . The transit time in this study was taken as the mean of 3-5 successive
heart beats. A change in transit time within a subject provides an accurate estimate
for a change in the overall arterial distensibility in that subject, because the length
of the arterial tree remains constant. The opening of the aortic valves (R-top in
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ECG signal) was taken as starting point. The onset of the distension waveform, as-
sessed by Vessel Wall Tracking, at a defined site on the right common femoral ar-
tery, was taken as die end-point. Vessel Wall Tracking is an ultrasound technique
which enables the transcutaneous measurement of the vessel diameter and diame-
ter change during consecutive heart beats *2.83_
Renal hemodynamics, i.e. effective renal plasma flow (ERPF) and GFR, were
measured by continuous infusion of PAH (MSD, West Point, PA, U.S.A.) and
inulin (Inutest; Laevosan Gesellschaft, Linz, Austria), respectively. After the bolus
injection, a continuous infusion was initiated using a syringe pump (Terumo
SYC-521; Terumo Corporation, Tokyo, Japan) ^ . After an equilibration period
of 120 min, a total of four blood samples were collected in heparinized glass tubes
(Monoject; Sherwood Medical, St Louis, MO, U.S.A.) at ten min intervals. Once
blood for measurements of progesterone and 17(3-estradiol was withdrawn in a
vacutainer glass tube (Monoject). The blood samples were centrifuged at 4 °C for
10 min at 1500 £ directly after sampling. All plasma and serum samples were
stored at -20 °C before assay. In the plasma samples both PAH and inulin were
measured as detailed elsewhere 85,86 Serum progesterone and 17(3-estradiol were
measured using commercially available radioimmunoassay kits: RSL direct pro-
gesterone and RSL direct 17f}-estradiol kit (ICN Biomedicals, CA, U.S.A.), re-
spectively. The clearances of PAH and inulin were calculated by dividing the
product of infusion rate and infusate concentration by the mean of plasma PAH
and plasma inulin concentration, respectively. Assuming an extraction ratio for
PAH of 90% ^ , we calculated renal plasma flow and renal blood flow (RBF) using
the formulas: 10/9 x ERPF and 10/9 x ERPF/(1-Hematocrit), respectively. We
calculated renal vascular resistance using the formula: (MAP/RBF)x80000. The
filtration fraction was obtained by taking the ratio of the inulin clearance (GFR)
and the renal plasma flow.
We determined thermoregulatory skin perfusion using laser-Doppler fluxmetry
(Periflux PF3; Perimed, Jarfalla, Sweden), with probe PF 308, wide band (12
kHz) mode, and time constant 0.2 s. Measurements were performed at the volar
side of the endphalanx and dorsal side of the interphalanx of the right third finger.
The mean value of two minutes recording was used for off-line analysis. Flux val-
ues were expressed in arbitrary units (Pu); calibrated to the periflux motility stan-
dard. Biological zero values, obtained during arterial occlusion, were subtracted
from the measured laser-Doppler fluxmetry levels. Skin temperature was meas-
ured at the dorsal side of the interphalanx of the right fourth finger using a Hew-
lett Packard 78214C monitor (Hewlett Packard, Boblingen, Germany).
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Total forearm blood flow (FBF) was determined using ECG-triggered strain-
gauge venous occlusion plethysmography (Periflow; JSI; Beerse, Belgium) and has
been described in detail elsewhere "*. In short, the cuff for venous occlusion was
placed just above the elbow. A mercury strain-gauge was placed around the arm,
3-5 cm distal to the lateral humeral epicondyle. The hand circulation was stopped
by inflating a wrist cuff to suprasystolic pressure, starting one minute before each
FBF measurement. Hence, FBF represents predominantly muscle blood flow *'.
FBF was measured over a period of four minutes. The mean of the last two min-
utes was used for calculations. A flow curve encompassed the time interval of five
heartbeats, during which venous occlusion (50 mmHg) was applied over three
heartbeats. Thus, on average, we measured 12 inflow curves/min.
MAP (mmHg) and heart rate (beats/min) were measured non-invasively over a
one minute period on the third finger of the left hand using a blood pressure
monitor (Finapres; Ohmeda, Englewood, CO, U.S.A.).
Venous compliance was determined as described elsewhere **. To measure venous
pressure and to take blood samples, we inserted a 20-gauge catheter into a vein of
the right forearm. A pressure transducer was placed 5 cm below the sternal angle.
Intravenous pressure was measured with a Hewlett Packard 78205C pressure
monitor. Forearm volume changes were measured using mercury strain-gauge ve-
nous occlusion plethysmography as described above. Measurements began 30
minutes after venepuncture. First, the upper arm cuff was inflated to a cuff pres-
sure of 25 mmHg and was kept inflated for three minutes. This time interval was
chosen to reach a steady state in arm volume and pressure. Thereafter, the cuff was
deflated for two minutes to minimize accumulation of interstitial fluid due to cap-
illary filtration. The concomitant changes in volume and intravenous pressure
during each cuff pressure step were derived from the values measured just before
and after deflation of the cuff. Subsequently, the same procedures were followed to
obtain volume/pressure ratios during cuff pressures of 30, 35, 40 and 50 mmHg.
Venous compliance was defined as the slope of the relationship, calculated by lin-
ear regression, of the forearm volume (dV, ml/100ml) on the ordinate with the ve-
nous pressure (dP, mmHg) on the abscissa.
Statistical analysis
Differences between LP and FP were analyzed by the Wilcoxon matched-pairs
signed-ranks test. Correlations between concomitantly measured variables in the
FP and LP, and between differences in potentially related variables were tested by
Spearman's rank correlation analysis. In the comparisons, a P-value of less than
5% was considered statistically significant.
We calculated detectable changes in the mean of variables (n=9, CX=0.05 and
P=0.10), assuming a normal distribution of the data. The minimum detectable
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changes were 23%, 4%, 48%, 9% and 6% for the venous compliance, transit
time, FBF, ERPF and GFR, respectively.
Table 1 . Characteristics of subjects.
Cycle day of Estradiol Progesterone
measurement (pg/ml) (ng/ml)
Age Body mass FP LP FP LP FP LP
Subjects (years) Parity index (kg/m)
1
2
3
4
5
6
7
8
9
32
20
36
21
33
21
36
24
39
0
0
0
0
0
0
0
1
2
21.7
27.5
20.7
24.7
22.5
23.1
23.1
J9.7
22.9
6
10
10
10
4
6
7
4
5
21
24
20
24
24
24
23
23
24
83
50
273
47
32
36
16
40
62
159
148
99
81
144
132
79
24
83
<0.25
<0.25
<0.25
<0.25
<0.25
<0.25
<0.25
0.28
<0.25
19.7
6.5
12.4
10.3
16.4
10.9
7.8
5.8
8.7
RESULTS
Table 1 lists the general characteristics of the study population and the serum lev-
els of 17(J-estradiol and progesterone in the FP and LP, respectively. In 7 of 9 cases
serum levels of 17(3-estradiol were higher in the LP than in the FP (p = 0.14). In
both the FP and the LP the 17(3-estradiol varied over a wide range. In the LP, pro-
gesterone also varied over a wide range.
Medians (and ranges) for hemodynamic and renal variables are listed in Table 2.
The most relevant variables are also shown in Fig. 1. Skin blood flow and skin
temperature were consistently lower, and GFR was higher in the LP. None of the
other variables differed significantly between the LP and the FP. Neither the abso-
lute values in the LP nor the magnitude of the change relative to the FP of all vari-
ables listed in Table 2 correlated with the serum level of progesterone in the LP,
with the change in serum level of 17P-estradiol between FP and LP, or with the ra-
tio of progesterone and 17p-estradiol in the LP.
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Table 2. Medians (with ranges) for hemodynamic variables and kidney function during the FP
and LP of the menstrual cycle (n=9). Median differences [with 95% confidence interval] are
listed. Changes in LP relative to FP were evaluated using the Wilcoxon matched-pairs signed-
ranks test. Pu, perfusion units.
Venous compliance x 100
(ml lOOmrmmHg')
Transit time
(ms)
Mean arterial pressure
(mmHg)
Heart rate
(beats/min)
Laser Doppler fluxmetry^,
(Pu)
Laser Doppler fluxmetry,^,
(Pu)
Temperature^
PC)
Forearm blood flow
(ml 100ml' min ' )
Glomerular filtration rate
(ml/min)
Renal blood flow
(ml/min)
Renal vascular resistance
(dyn s cm'')
Filtration fraction
(GFR/RPF)
FP
5.5
(4.8-8.0)
207
(194-217)
87
(75-97)
61
(49-71)
54.2
(16.7-124)
6.2
(2.1-13.2)
31.4
(27.6-33.5)
2.7
(1.2-5.4)
112
(98-129)
852
(670-1006)
8955
(7131-10420)
0.21
(0.17-0.27)
LP
6.6
(4.4-8.8)
202
(195-221)
87
(61-93)
64
(55-75)
29.6
(9.5-59.8)
5.0
(1.5-26.1)
27.0
(24.1-32.2)
1.8
(1.2-2.4)
123
(105-129)
889
(666-1062)
7499
(6291-10575)
0.22
(0.19-0.30)
Median
difference
+0.7
[-1,7*->+3.0]
0
[-13<->+7]
0
[-13<->+3]
+6
[-7<-»+7]
-17.8
[-66.4<->-5.8]
-0.4
[-7.9<->+2.0]
-1.9
h4.8«-»-0.6]
-0.4
[-1,0<->+0.4]
+7
[0<-»+11]
+24
[-26<->+110]
-376
[-2040<->+374]
+0.01
|0<-»+0.02]
P-val
0.33
0.78
0.18
0.31
0.02
0.86
0.04
0.10
0.03
0.17
0.21
0.31
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Figure 1. Skin blood flow [measured by laser-Doppler fluxmetry (LDF)] (aA FBF CW GFR fc) and RBF
(Q[) during the menstrual cycle. Each pair of open circles represents one subject, a filled square rep-
resents the median of that menstrual phase. FP, follicular phase; LP, luteal phase; M, menstrual
period; 0, ovulation.
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Continued figure 1.
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DISCUSSION
The objective of this study was to determine whether there are signs of vascular re-
laxation in the LP of the menstrual cycle. Arterial blood pressure, vascular tone
and the blood flows to the forearm and kidneys were comparable in the LP and
FP. In contrast, skin thermoregulatory blood flow was consistently lower, and the
GFR higher in the LP of the menstrual cycle.
The LP is not only characterized by the appearance of progesterone in the periph-
eral blood, but also by a highly variable serum level of 17(3-estradiol, known to be a
significant modulator of vascular tone. Most studies on vascular effects in response
to estrogen have shown a vasodilatory action "*\ In our study the luteal value for
serum 17(3-estradiol was higher in 7 out of 9 subjects when compared with that in
the FP (Table 1). We did not find a correlation between the change in serum level
of 17[i-estradiol between the two phases, and all the hemodynamic and renal van-
ables measured.
Based on reported studies 78-80^  ^ g expected to see an increase in both the venous
compliance and arterial distensibility leading to a fall in pulse-wave velocity and a
rise in transit time, respectively. However, our measurements suggested that nei-
ther the venous compliance nor the arterial distensibility had changed consistendy
in the LP. Other studies investigating venous distensibility during the menstrual
cycle, show conflicting data ^.91 y^g reproducibiliry of pulse-wave velocity
measurements can be adversely affected by changes in arterial blood pressure ^ .
Because of the lack of consistent change in MAP in our study, we did not correct
for coincidental fluctuations in blood pressure.
Vasodilatation in response to a fall in arteriolar tone can be expected to give rise to
hyperperfusion in muscle and skin tissue for example. Instead, we found a consis-
tent reduction in skin thermoregulatory blood flow and a trend towards lower per-
fusion rates in forearm muscle during the LP. Other investigators have not found a
consistent change in FBF either 93-%_ Observed changes in skin blood flow during
the menstrual cycle are conflicting; varying between no change 93,97.98^  ^  increase
in LP w-i°° and a decrease in LP ' ° ' ' ° ' . The fall in skin thermoregulatory blood
flow as observed in the present study is possibly related to the well-known 0.3-0.5
°C increase in core temperature during the LP. This increase in core temperature
may result from either a raised metabolic rate or an increase in thermal body insu-
lation. It follows that the higher body temperature is probably an intended effect
in response to a rise in the set-point of the thermoregulatory center in the medulla
oblongata. This effect can be obtained by a fall in thermoregulatory skin flow (ar-
teriovenous shunt flow) "". The blood flow to the skin of the finger tip is more in-
fluenced by thermoregulation than is the case on the dorsal side of the finger,
where arteriovenous shunts are relatively scarce. The consistent fall in just the fin-
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ger tip flow supports the view that the observed changes in skin flow reflect those
in thermoregulation.
To our knowledge the cyclicity in the GFR has never been evaluated by measuring
serum inulin clearance; in other words, all data on this topic reported so far are
based on GFR markers such as creatinine clearance or ^'Cr-EDTA clearance. We
showed a 10% rise in median GFR in conjunction with a trend towards higher
RBF and lower renal vascular resistance in the LP. Other investigators reported ei-
ther a similar cyclicity 9-11.103 ^j. j g ^ of cyclicity "^, probably due to differences
in methodology. The combined increase in both GFR and RBF in five of six sub-
jects supports the view that the mechanism of this increase is afferent arteriolar di-
lation. However, this requires further study.
The observed blood flow patterns to muscle, skin and kidney do not support our
hypothesis of a general vascular relaxation in the LP. Since we studied the blood
flows to only three vascular beds, it was impossible to draw conclusions about
changes in total peripheral resistance with the menstrual cycle. However, it has
been demonstrated that total peripheral resistance decreases in the LP of the men-
strual cycle * -^\
A limitation of these /« w'vo experiments is the relatively high variability resulting
from die combination of biological variation (2-week interval) and the use of indi-
rect measurement techniques. In our institute this combined variability is associ-
ated with coefficients of variation ranging from 10 to 25 % 8®.>06 Since the
measurements were paired and performed by the same investigator, we expected
to minimize this problem. Table 2 shows the 95%-confidence intervals of the me-
dian differences for each of the measured variables. Although some variables are
characterized by relatively wide intervals (modest power), others show relatively
narrow intervals. The minimum detectable changes mentioned above do support
diese findings and illustrate, in combination with the actual measured changes,
the possibility of a type II error.
In conclusion, the present data do not support the concept of a general vascular re-
laxation during the LP of the menstrual cycle. Thermoregulatory blood flow in the
skin was most probably diminished in LP, in order to raise the core temperature.
Post-ovulatory vasodilatation of afferent renal arterioles could be responsible for
the raised GFR, and possibly the endocrine environment of the LP induces selec-
tive vasorelaxation in certain vascular beds.
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iABSTRACT
This study was designed to investigate whether total peripheral resistance de-
creases and plasma volume and extra-cellular fluid volume increase in the luteal
phase of the menstrual cycle relative to the follicular phase.
We measured in both luteal and follicular phase of the menstrual cycle, cardiac
output (echocardiography), blood pressure (semi-automatic oscillometry), plasma
volume ('^I-human albumin dilution technique), extra-cellular fluid volume (so-
dium bromide dilution technique) and the plasma levels of their regulatory neuro-
hormones (renin-angiotensin-aldosterone system, ANP and catecholamines).
Measurements were performed in two consecutive menstrual cycles during a low-
and during a high-salt diet. The data points obtained in the luteal phase were com-
pared with those in the follicular phase of the same menstrual cycle. The follicular
phases of the two consecutive menstrual cycles with different salt intake were com-
pared with each other. All comparisons were performed by non-parametric tests.
Switching to a high-salt diet led to a lower activity of the renin-angiotensin-
aldosterone system and a lower plasma norepinephrine concentration, together
with a higher plasma aerial natriuretic peptide concentration, body weight and
extra-cellular fluid volume. Only in the high-salt menstrual cycles, we observed in
the luteal phase relative to the follicular phase of the menstrual cycle, a lower total
peripheral resistance and a higher renin-angiotensin-aldosterone system activity
together with a trend towards a lower ANP. These changes were not paralleled by
a concomitantly higher extra-cellular fluid volume or plasma volume.
These data suggest a lower arterial tone in the luteal phase of the menstrual cycle, a
condition that triggers endocrine changes consistent with arterial underfill.
INTRODUCTION
In human pregnancy plasma volume (PV) increases by approximately 40% *" .^
Nowadays, it is widely accepted that the primary trigger for changes in blood vol-
ume during pregnancy is initial systemic arterial vasodilation with relative under-
filling of the arterial circulation ^ . Reported hemodynamic changes in the
menstrual cycle mimic hemodynamic adaptations seen in early pregnancy. These
cyclic changes consist of a slight decrease in mean arterial pressure (MAP) ?, and
are paralleled by a rise in plasma renin activity " , a rise in glomerular filtration rate
(GFR) ' ' and effective renal plasma flow (ERPF) "", and a downward reset of os-
motic thresholds for thirst and vasopressin release in the luteal phase (LP) *.
Whether the latter cyclic changes in volume homeostasis are also secondary to sys-
temic arterial vasodilation with a compensatory expansion of the blood volume, is
unknown.
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The present study was designed to test the hypothesis that, compared to the fol-
licular phase (FP), total peripheral resistance (TPR) has decreased while PV and
extracellular fluid volume (ECFV) have increased in the LP of the menstrual cycle.
To this end, we measured the following parameters in both phases of the men-
strual cycle: TPR, blood pressure (BP), PV, ECFV and their regulatory neurohor-
mones (active plasma renin concentration (APRC), angiotensin II (Angll),
aldosterone (Aldo), atrial natriuretic peptide (ANP) and catecholamines). Since
changes in these parameters are determined, in part, by sodium intake, we per-
formed our experiments during both a low- and a high-salt diet.
MATERIALS AND METHODS
Subjects
Experiments were performed in 29 healthy volunteers (mean age: 22 ± 4 (SD)
years; mean body mass index: 22 ± 3 (SD) kg/m^) with a history of regular men-
strual cycles (29 ± 3 days). All participants gave written informed consent and the
study was approved by the hospital's medical ethics committee. The investigation
conforms with the principles outlined in the Declaration of Helsinki.
Protocol
A total of four measurements were performed divided over two consecutive men-
strual cycles, in each cycle once in the follicular phase (FP), between the third - and
seventh day, and once in the LP, between the 20th - and 24th day. During one cy-
cle the subjects used a sodium-restricted diet of 50 mmol/day and during the other
a high-sodium diet of 220 mmol/day. They started the diet seven days before each
measurement. Each subject was randomized for type of diet to start with. Accord-
ingly, half of the subjects started with the low-salt diet, and the other half with the
high-salt diet. They collected a 24-hour urine sample for determination of sodium
and creatinine contents the day before each measurement. Compliance with the
diet was assessed by the 24-hour sodium excretion. Completeness of urine collec-
tion was verified by 24-hour creatinine excretion. Measurements started at 8.00
a.m., after an overnight fast, and ended at 1.00 p.m.. The subjects were asked not
to smoke and not to drink beverages containing caffeine or alcohol, and to drink
water only, on the day of the measurements. Experimental conditions were similar
on each of the four study days. The measurements were performed with the sub-
ject in supine position and were started after an acclimatization period of at least
30 min. The subjects were asked to drink a solution containing sodiumbromide
(20.0 ml, 150 mmol/1) so as to quantify the size of the ECFV. Just before the accli-
matization period a 20-gauge catheter was inserted into a vein of the left forearm
in order to take blood samples. Blood samples were collected for measurement of
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hematocrit (Ht), osmolality, albumin, progesterone, 17(3-estradiol, catechola-
mines (norepinephrine, epinephrine and dopamine), APRC, Angll, Aldo, ANP
and bromide. Blood samples for the measurement of the latter hormones and bro-
mide were centrifuged at 4° C for 10 min at 1500 g, immediately after sampling,
and stored deep-frozen before assay. The other blood samples were sent to the rou-
tine hospital laboratories for direct determination. Besides sampling, echocardio-
graphic measurements were performed, followed by determination of the PV.
Measurements
t Plasma volume (CV 4.2%) was measured, at approximately the same time in the
_ morning, as follows " ° . Five |iCi '^I-human albumin, dissolved in 1 ml saline,
| was given intravenously at time zero (total body dose of irradiation = 0.04 mSv).
I Before the bolus injection and again after 10, 20 and 30 min, blood samples (5ml)
Jj were drawn to determine the volume specific plasma radioactivity. The virtual vol-
• ume specific plasma radioactivity at time zero, was calculated by extrapolation us-
g> ing the three serially obtained volume specific plasma radioactivity data points
•6 after bolus injection. PV was calculated by dividing the total injected radioactivity
I by the virtual volume specific plasma radioactivity at time zero, corrected for
"f blanks.
f ECFV was determined with sodium bromide on the basis of its distribution space,analogous to the above mentioned '^I-human albumin dilution for determina-
^ tion of PV " ' . Sodiumbromide (4.50 mmol) was given orally at time zero. Prior
t to intake (blank value) and again after a 4 h equilibration period a blood samplewas taken. Determination of bromide in these samples was performed by capillary
gas chromatography (CV 4%) " ' . Bromide space was calculated by dividing the
orally administered dose of bromide by the concentration of serum bromide after
correction for blanks.
Echocardiographic measurements, as described in detail elsewhere "^, were per-
formed in semi-left lateral position. The echocardiographic recordings were made
with a cross-sectional, phased array echocardiographic Doppler system (Hewlett-
Packard Sonos 500 and 1000). Cardiac output (CO) was calculated according to
the formula: CO = stroke volume (SV) x heart rate (HR). To determine SV, blood
flow velocity was measured across the aortic valve. SV was calculated as aortic area
x aortic velocity integral. TPR was calculated by using the formula TPR
(dyn.s.cm'5) = MAP (mmHg) x 80 / CO (1/min). In this formula, the MAP was
calculated as the average of three recordings during measurement of the flow
across the aortic valve using a semi-automatic oscillometric device (Dinamap Vital
Signs Monitor 1846, Critikon, Tampa, FL, USA).
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The hematocrit, as well as the serum osmolality and albumin were measured by
standard laboratory techniques. Serum 17p-estradiol and progesterone were de-
termined using reagent kids of DPC (DPC, Los Angeles, Cal.). These assays are
based on solid-phase radioimmunoassays using coated tube technology. Sensitiv-
ity of the assays are 0.035 and 0.15 nmol/1, respectively. In the measurements of
these two steroids, precision is better than 5%.
APRC was assessed by the IRMA-method (Nichols Institute Diagnostics, Wy-
chen, The Netherlands) with an intra-assay coefficient of variation (CV) of 2.9%
and an inter-assay CV of 7.6% "^. Angll was determined by radio-immunoassay
(RIA) following Ph Phenyl column extraction (Amersham Int. Amersham, UK;
intra-assay CV 4.6% and inter-assay CV 7.7%) ' '^. Aldo was assayed by means of
a solid-phase protein binding RIA (Diagnostic Products Corporation, LA, USA;
intra- and inter assay CV 4.3% and 6.7% resp.) ' ' -\ ANP was measured by a com-
petitive protein-binding radio-immunoassay (RIA) (Nichols Institute Diagnos-
tics) following extraction of plasma over Sep-Pak C18 columns ' " \
Norepinephrine (intra-assay CV 4.5%, inter-assay CV 8.1%), epinephrine
(intra-assay CV 4.1 %, inter-assay CV 8.6%) and dopamine (intra-assay CV 3.9%,
inter-assay CV 7.1 %) were assessed by a sensitive fluorimetric method, in which
catecholamines are concentrated from plasma by liquid-liquid extraction and deri-
vatized with a selective fluorescent agent prior to chromatography "^. For each
substance, all samples from the same individual were assayed in a single run.
Statistical analysis
Only ovulatory cycles were included for analysis of the differences between LP and
FP, whereas all the cycles were included for analysis of differences between the
FP's. A menstrual cycle was considered ovulatory when the mid-luteal serum pro-
gesterone concentration exceeded 15 nmol/1 "'.
Differences between LP and FP in each cycle (low and high-salt diet, « = 12 and 14
resp.), and in the FP between the two salt diet cycles (« = 25) were analyzed by the
Wilcoxon Matched-Pairs Signed-Ranks Test. Correlations between concomi-
tantly measured variables or between differences in potentially related variables
were tested by Spearman's rank correlation analysis. In the comparisons a /"-value
of less than 5% was considered statistically significant.
We calculated detectable changes in the mean of variables (« = 14, a = 0.05 and P
= 0.10), assuming a normal distribution of the data. The minimal detectable
changes were 7.2%, 11.5%, 3.2%, 10.1% and 10.7% for the PV, ECFV, MAP,
CO and TPR, respectively.
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IRESULTS
Twenty-five of the 29 subjects completed all measurements (two menstrual cy-
cles), whereas four subjects completed the two measurements in a single menstrual
cycle (three low-salt menstrual cycles, one high-salt menstrual cycle). Four of the
in total 54 menstrual cycles (one low-salt menstrual cycle, three high-salt men-
strual cycles) were excluded from analysis because of irregular blood loss. Fourteen
of the 23 (61%) high-salt menstrual cycles and twelve of the 27 (44%) low-salt
menstrual cycles were ovulatory.
In the high-salt cycles as compared to the low-salt cycles (FP, « = 25), plasma con-
centration of norepinephrine was 26% (median, /"< 0.001) lower, and ECFV and
body weight were 6% (median, /> < 0.05) and 1% (median, P < 0.01) higher, re-
spectively. When subjects used a high-salt diet, the activity of the renin-
angiotensin-aldosterone (RAA)-system was lower as compared to that in a low-salt
diet. Using the follicular value in low-salt cycles as 100%, the following follicular
figures in high salt cycles were obtained: APRC 67% (median, /> < 0.001), Angll
77% (median, P< 0.01) and Aldo 24% (median, P< 0.001). The latter was paral-
leled by elevated ANP levels: 119% (median, /" < 0.01).
Tables 1A and IB list the hormonal status and urinary sodium excretion of the
subjects during low- (« = 12) and high-salt (« = 14) diet, respectively. In the LP
relative to the FP, serum 17(3-estradiol and progesterone had increased in both
low- and high-salt menstrual cycles. Catecholamines and sodium excretion did
not differ between LP and FP in both low- and high-salt menstrual cycles.
Tables 2A and 2B list the changes in central hemodynamics and body fluid vol-
umes in the menstrual cycle during low- (» = 12) and high-salt (« = 14) diet, re-
spectively. During the low-salt menstrual cycles none of the measured variables
changed consistently. On the other hand, during the high-salt menstrual cycles
TPRand albumin had decreased in the LP by a median of 5.3% and 2.6%, respec-
tively, and osmolality tended to decrease (P = 0.06). None of the other variables
listed in Table 2B had changed consistently as a function of the menstrual cycle.
The volume regulatory hormones measured in the two phases of the two men-
strual cycles studied are listed in Tables 3A and 3B. In the LP of both low- and
high-salt menstrual cycles the hormones of the RAA-system were elevated relative
to the FP. Plasma ANP concentration was significantly lower in the LP of low-salt
menstrual cycles and tended to be lower in the LP of high-salt menstrual cycles (P
= 0.14).
In both low and high-salt menstrual cycles, the change in TPR, APRC or ANP did
not correlate with the change in serum progesterone -, serum 17(3-estradiol con-
centration, nor the ratio of serum progesterone to serum 17|3-estradiol. Cyclic
changes in PV, ECFV, APRC or ANP during both low- and high-salt menstrual
cycles did not correlate with the concomitant changes in TPR.
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Table 1A. Hormonal characteristics and sodium excretion of subjects (n = 12) during the FP
and LP of fow-sa/t mensfrua/ cyc/es.
FP LP Median difference
17(5-estradiol(nmol/l)
Progesterone (nmol/l)
Norepinephrine (nmol/l)
Epinephrine (nmol/l)
Dopamine (nmol/l)
0.10(0.08-0.12) 0.32(0.27-0.36)** +0.22 (+0.14 <->+0.28)
2.1(1.3-2.3) 25.3(20.4-45.0)** +22.7 (+18.6 <-» +47.3)
0.63(0.54-1.10) 0.65(0.61-0.79) +0.00 (-0.19 «-> + 0.13)
0.06 (0.04-0.09) 0.04 (0.02-0.06) -0.02 (-0.04 <-> +0.00)
0.13(0.08-0.19) 0.14(0.08-0.17) +0.01 (-0.08 «-»+0.09)
Sodium excr. (mmol/24h) 56 (38-66) 46 (34-86) + 1.0{-27<->+42)
Values during the FP and LP are medians and interquartile ranges. Median differences (with
95% confidence interval) are listed in the final column. Changes in variables during the men-
strual cycle were evaluated using the Wilcoxon matched-pairs signed ranks test, **p < 0.01,
***p < 0.001. FP, follicular phase; LP, luteal phase.
Table 1B. Hormonal characteristics and sodium excretion of subjects (n =14) during the FP and
LP of /)/gb-sa/f mensfrua/ cyc/es.
FP LP Median difference
17p"-estradiol (nmol/l)
Progesterone (nmol/l)
Norepinephrine (nmol/l)
Epinephrine (nmol/l)
Dopamine (nmol/l)
0.10(0.06-0.12)
1.6(1.2-2.6)
0.47(0.41-0.77)
0.06 (0.05-0.09)
0.13(0.09-0.22)
0.36(0.26-0.45)*'
31.2(27.5-36.0)*"
0.59(0.45-0.76)
0.04 (0.03-0.09)
0.14(0.07-0.24)
Sodium excr. (mmol/24h) 220(172-279) 200 (156-244)
+0.28 (+0.13 <-> +0.35)
+29.0 (+24.4 <-> +38.0)
+0.06 (-0.08 <-> +0.26)
-0.02 (-0.05 <-> +0.02)
-0.03 (-0.06 <-> +0.07)
-13 (-101 <->+66)
Values during the FP and LP are medians and interquartile ranges. Median differences (with
95% confidence interval) are listed in the final column. Changes in variables during the men-
strual cycle were evaluated using the Wilcoxon matched-pairs signed ranks test, **p < 0.01,
***p < 0.001. FP, follicular phase; LP, luteal phase.
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Table 2A. Central hemodynamics and body fluid volumes during the FP and LP of /ow-sa/t
mensf/i/a/ cyc/es (n = 12).
FP LP Median difference
i
MAP (mmHg)
Stroke volume (ml/min)
Cardiac output (l/min)
TPR(dyn.s.cm')
Plasma volume (ml)
Hematocrit
ECFV (I)
Body weight (kg)
Osmolality (mosm/kg)
Serum albumin (g/l)
79 (74-84)
78.0 (74.0-79.0)
5.10(4.50-5.40)
1338(1226-1424)
2466(2128-2792)
0.37 (0.33-0.37)
17.9(13.9-19.5)
60.3(56.1-62.7)
281(278-282)
39.3 (37.9-40.4)
78 (72-82)
80.0 (75.0-82.0)
5.30 (4.40-5.60)
1204(1067-1413)
2542(2179-2634)
0.37 (0.34-0.38)
16.1 (15.1-20.3)
59.9 (55.9-63.7)
278 (275-283)
39.0 (37.9-40.5)
-3 (-7«-» +3)
+ 1.0 (-10.0 <-»+4.0)
-0.05 (-0.40 <-> +0.90)
-60 (-352 <-> +171)
-54 (-202 <-> +168)
+0.00 (-0.01 <->+0.01)
-0.1 (-0.9<-»+1.1)
-0.4 (-0.9 <->+1.0)
-3.0 (-7.0 «-> +2.0)
-0.3 (-2.1 <->+2.3)
Values during the FP and LP are medians and interquartile ranges. Median differences (with
95% confidence interval) are listed in the final column. Changes in variables during the men-
strual cycle were evaluated using the Wilcoxon matched-pairs signed ranks test, *p < 0.05,
**p < 0.01. FP, follicular phase; LP, luteal phase; MAP, mean arterial pressure; TPR, total pe-
ripheral vascular resistance; ECFV, extracellular fluid volume.
Table 2B. Central hemodynamics and body fluid volumes during the FP and LP of h/gh-sa/f
menstrua/ cyc/es (n = 14).
FP LP Median difference
MAP (mmHg)
Stroke volume (ml/min)
Cardiac output (l/min)
TPR (dyn.s.cm '*)
Plasma volume (ml)
Hematocrit
ECFV (I)
Body weight
Osmolality (mosm/kg)
Serum albumin (g/l)
82 (77-85)
76.0(69.0-84.5)
4.70(4.50-5.25)
1336(1226-1453)
2514(2247-2673)
0.35 (0.33-0.37)
17.4(15.1-21.4)
62.5(55.6-67.0)
282 (278-284)
38.9 (36.8-40.2)
78 (75-83)
78.0(68.5-81.3)
4.85 (4.40-5.28)
1320(1178-1441)*
2463(2168-2868)
0.35 (0.34-0.36)
17.7(15.5-21.3)
61.3(55.2-66.8)
277 (276-280)
37.3 (36.8-38.7)*
-0.5 (-4.0 <->+5.0)
-0.05 (-0.5 <-» +0.6)
-71 (-179<->-10)
-52 (-159 <-> +244)
+0.00 (-0.02 <-> +0.01)
+0.2 (-1.2<->+1.6)
-0.2 (-1.1 <->+1.4)
-5.0 (-9.0*-*+2.0)
Values during the FP and LP are medians and interquartile ranges. Median differences (with
95% confidence interval) are listed in the final column. Changes in variables during the men-
strual cycle were evaluated using the Wilcoxon matched-pairs signed ranks test, *p < 0.05,
**p < 0.01. FP, follicular phase; LP, luteal phase; MAP, mean arterial pressure; TPR, total pe-
ripheral vascular resistance; ECFV, extracellular fluid volume.
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Table 3A. Neurohormones during the FP and LP of fow-sa/f menstrua/ cyc/es (n = 12).
FP LP Median difference
APRC(mU/l) 28.4(16.3-37.9) 35.7(32.6-46.8)** +9.8 (+4.2 <-> +20.4)
Angll (pmol/1) 9.1(8.1-11.2) 12.1 (10.2-14.6)** +2.2 (+1.0 <-> +5.2)
Aldo(nmol/1) 270(181-470) 643 (589 -854 ) * * +354 (+139 <->+484)
ANP(pg/ml) 68.5(53.8-101.8) 60.0(49.1-76.5)* -7 .0 (-20.0 <-> -2.0)
Values during the FP and LP are medians and interquartile ranges. Median differences (with
9 5 % confidence interval) are listed in the final column. Changes in variables during the men-
strual cycle were evaluated using the Wilcoxon matched-pairs signed ranks test, */> < 0.05,
* * / > < 0 .01 , * * * P < 0 .001. FP, follicular phase; LP, luteal phase; APRC, active plasma renin;
Angl l , plasma angiotensin II; Aldo, plasma aldosterone; ANP, atrial natriuretic peptide.
Table 3B. Neurohormones during the FP and LP of n/gh-sa/f menstrua/ cyc/es (n = 14).
FP LP Median difference
APRC(mU/l) 18.1(10.7-24.6) 26.1 (15.3-37.3)** +7.5 (+0.9 <-» +14.8)
Angll (pmol/l) 7.8(6.1-10.8) 8.6(7.1-12.6)* +1.3 (+0.1 <-> +3.1)
Aldo(nmol/ I ) 97.5(10.0-193) 255(166-446) * * +198 (+3.0 «-> +313)
ANP(pg/ml) 111.5 (52.8-147.0) 85.5(67.0-102.0) - 32 .0 (-50.0 <-> +12.0)
Values during the FP and LP are medians and interquartile ranges. Median differences (with
9 5 % confidence interval) are listed in the final column. Changes in variables during the men-
strual cycle were evaluated using the Wilcoxon matched-pairs signed ranks test, *P < 0.05,
* * P < 0 .01, * * * P < 0.001. FP, follicular phase; LP, luteal phase; APRC, active plasma renin;
Angl l , plasma angiotensin II; Aldo, plasma aldosterone; ANP, atrial natriuretic peptide.
DISCUSSION
The present study was designed to evaluate changes in TPR in the FP and the LP
of the menstrual cycle, and to explore whether a fall in TPR is paralleled by a rise in
PV as has been proposed for early pregnancy '"^. Subjects on a high-salt diet had a
median 5% fall in TPR in the LP relative to the FP. Most likely, this decrease is
triggered by a fall in vascular tone which again activates volume retaining mecha-
nisms as is suggested by the increase in levels of RAA and a trend towards a lower
ANP. The fact that PV and ECFV did not increase appreciably may be related to
insufficient power in this particular study (minimal detectable change 7.2% and
11.5%, resp.) to detect a small rise in volume. In order to reduce the scatter in data
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points caused by variation in salt intake, we asked the subjects to adhere strictly to
their salt diet. In their study, in which subjects did not use a standardized salt diet,
Chapman et al ^ did neither find an increase in PV in the LP of the menstrual cy-
cle. T o our opinion the PV changes with the menstrual cycle are probably too
small to be discerned with currently available techniques, which do not allow serial
measurements throughout the menstrual cycle.
It is tempting to speculate that the 2 6 % higher plasma norepinephrine concentra-
tion during the low-salt diet led to a higher basal vascular tone during the two ses-
sions in that state. A higher vascular tone during low-salt menstrual cycles may
t h a v e blunted the arterial relaxation in the LP. T h e body weight was approximately
0.7 kg (median) higher during high-salt diet than during the period of low-salt in-
3 take. T h e concomitant larger size of E C F V suggests that the higher body weight
| resulted from an increase in total body water.
." T P R was calculated by dividing the MAP by the simultaneously measured C O .
• Cont inuous wave Doppler measurement of flow in the aortic valve has been found
8> to provide a reliable and reproducible estimate for stroke volume "*• ' " . Kusu-
•g moto et al ' ^ demonstrated that continuous wave Doppler estimates of CO can
| be used to reliably detect serial changes in CO in response to various interventions.
"g Our present observations of a lower TPR in the LP confirms previous studies on
f this subject 105.109,121 j ^ ^imal studies and in-vitro 78-80, both 17(3-estradiol and
f progesterone can be held responsible for the observed decrease in TPR. Therefore,
we expected to find a correlation between change in serum 17P-estradiol concen-
* tration, change in progesterone concentration and/or the ratio of serum progester-
t one to 17P-estradiol on the one hand and change in TPR on the other hand. Thefact, that we did not find such correlations indicates that the interaction between
the endocrine changes during the menstrual cycle and the subsequent hemody-
namic adaptation do not follow a simple dose-response relationship.
We postulate that fluid retention leading to a small increase in ECV and PV accel-
erates secondary to arterial relaxation in the LP. Evidence for this accelerated fluid
retention is provided by the luteal increase in RAA-system activity together with a
modest fall in plasma ANP concentration. Besides these endocrine changes, other
factors are to be involved since neither the changes in APRC nor that in ANP cor-
related with those in TPR. The increase in APRC during the LP of the menstrual
cycle has been reported by several other investigators'3-15,109. This increase is as-
sumed to be a compensatory response to the natriuretic effect of progesterone ^ .
The lack of correlation between changes in APRC and changes in serum proges-
terone concentration indicates that other factors contribute to the APRC rise in
the LP of the menstrual cycle. The fact that changes in TPR did not correlate with
changes in sex steroids as well as changes in APRC makes it difficult to identify
from this study the mechanism that leads to the increased RAA-system activity.
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The concurrent decline in plasma ANP concentration during the LP suggests the
physical perception of intravascular volume depletion.
In conclusion, the present study demonstrates a modest decrease in TPR in the LP
of the menstrual cycle. Simultaneously, we observed an increase in RAA-system
activity and a tendency to a lower plasma ANP concentration. Despite the activa-
tion of sodium and fluid retaining mechanisms, ECFV and PV did not increase
appreciably in the LP of the menstrual cycle. Apparently, the stimulus of arterial
relaxation, and subsequent arterial underfill, in the LP of the menstrual cycle is,
compared to early pregnancy, too weak to elicit a measurable rise in ECFV and
PV.
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IABSTRACT
This study was designed to test the hypothesis that the reported general vascular
relaxation, including that in the renal vasculature, in very early pregnancy is also
noticeable in the luteal phase of the menstrual cycle.
We measured in both luteal and follicular phase of the menstrual cycle, cardiac
output, blood pressure, glomerular filtration rate, effective renal plasma flow and
forearm blood flow. Measurements were performed in two consecutive menstrual
cycles once on a low- and once on a high-salt diet. The data points obtained in the
luteal phase were compared with those in the follicular phase of the same men-
strual cycle. The follicular phases of the two menstrual cycles with exposure to two
different salt-intakes were compared with each other. All comparisons were per-
formed using non-parametric tests.
Only during high-salt menstrual cycles, we observed consistent changes with the
menstrual cycle. Changing to a high-salt diet caused a decrease in plasma norepi-
nephrine concentration and an increase in both glomerular filtration rate and fil-
tration fraction. In the luteal phase total peripheral resistance was lower as
compared to the follicular phase. As compared to the follicular phase, effective re-
nal plasma flow and glomerular filtration rate were higher, and filtration fraction
and renal vascular resistance lower in the luteal phase. Forearm blood flow and
vascular resistance were comparable in the two phases of the menstrual cycle.
The results of this study provide evidence for a decrease in both total peripheral re-
sistance and renal vascular resistance without consistent change in forearm vascu-
lar resistance in the luteal phase of the menstrual cycle. The glomerular filtration
rate in the luteal phase has increased in concert with an increase in effective renal
plasma flow and a decrease in filtration fraction. The hemodynamic changes in-
duced by the endocrine environment of the luteal phase of the menstrual cycle
mimic the hemodynamic adaptation to early pregnancy.
INTRODUCTION
The hemodynamic adaptation to pregnancy is characterized by the concomitant
decrease in systemic and renal vascular resistances shortly after implantation and
before blood volume (BV) expansion. Systemic arterial vasodilation, giving rise to
a fall in filling pressure in the arterial vasculature, has been proposed as the pri-
mary trigger for the increase in BV during pregnancy *"^ . The hemodynamic ef-
fects of this primary trigger are decreased systolic and diastolic blood pressures,
increased cardiac output, stimulation of the renin-angiotensin-aldosterone axis,
non-osmotic stimulation of thirst and vasopressin release, and renal sodium and
water retention with expansion of the extracellular fluid volume (ECFV) and
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plasma volume (PV) compartments. In addition, renal arterial vasodilation leads
to a 50-60% increase in renal blood flow (RBF) and a 40-50% increase in glom-
erular filtration rate (GFR). However, to the best of our knowledge, there is no
other condition in mammalian physiology with, at the same time, expansion of
the ECFV including PV and a markedly increased GFR. The mediator(s) of these
very early (within three weeks of conception) circulatory adaptations is (are) still
unknown.
Some of the hemodynamic changes seen in early pregnancy, although with a
smaller amplitude, have been reported to take place in the luteal phase (LP) of the
menstrual cycle. These changes consist of a fall in mean arterial pressure (MAP) ,^
a rise in GFR 12.123 ^ ^j plasma renin activity '*, and a lowering of the osmotic
thresholds for thirst and vasopressin release .^ Most of these phenomena seem to
represent compensations developing in response to peripheral arterial vasodilation
resembling that in pregnancy. Recently, evidence for a combined decrease in sys-
temic and renal vascular resistance in the LP of the menstrual cycle has been re-
ported "^. However, the sodium intake by the subjects in that study was not
standardized throughout the menstrual cycle of measurement, an approach that
may have influenced particularly the renal data.
The present study was designed to test the hypothesis that the reported general
vascular relaxation, including that in the renal vasculature, in very early pregnancy
is not only noticeable in the LP of the menstrual cycle, but also, that this effect is
dependent upon sodium intake. To this end, we measured in both phases of two
consecutive menstrual cycles with the subjects using a low-salt and a high-salt diet
(or vice versa), respectively, cardiac output (CO), blood pressure (BP), GFR, ef-
fective renal plasma flow (ERPF) and forearm blood flow (FBF).
MATERIALS AND METHODS
Subjects
Experiments were performed in 29 healthy volunteers (mean age: 22 ± 4 (SD)
years; mean body mass index: 22 ± 3 (SD) kg/m^) with a history of regular men-
strual cycles (29 ± 3 days). All participants gave written informed consent and the
study was approved by the hospital's medical ethics committee. The investigation
conforms with the principles outlined in the Declaration of Helsinki.
Protocol
A total of four measurements were performed divided over two consecutive men-
strual cycles, in each cycle once in the follicular phase (FP), between the third - and
seventh day, and once in the LP, between the 20th - and 24th day. During one cy-
cle the subjects used a sodium-restricted diet of 50 mmol/day and during the other
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a high-sodium diet of 220 mmol/day. They started the diet seven days before each
measurement. Each subject was randomized for type of diet to start with. Accord-
ingly, half of the subjects started with the low-salt diet, and the other half with the
high-salt diet. They collected a 24-hour urine sample for determination of sodium
and creatinine contents the day before each measurement. Compliance with the
diet was assessed by the 24-hour sodium excretion. Completeness of urine collec-
tion was verified by 24-hour creatinine excretion. Measurements started at 8.00
a.m., after an overnight fast, and ended at 1.00 p.m.. The subjects were asked not
to smoke and not to drink beverages containing caffeine or alcohol, and to drink
water only, on the day of the measurements. Experimental conditions were similar
on each of the four study days. Determinations of forearm blood flow and renal
hemodynamics took place in a temperature-controlled room (25-26 °C).
All biophysical measurements were performed with the subject in supine position
and the arm under investigation at heart level. Data acquisition was started after
an acclimatization period of at least 30 min. Before the acclimatization period,
20-gauge catheters were inserted into a vein of both the right forearm for infusion
of para-aminohippurate sodium (PAH) and inulin (see below) and the left fore-
arm for blood sampling. At least 20 min after insertion of the catheter in the left
forearm blood samples were drawn for measurement of progesterone, 17P-estr-
adiol, catecholamines (norepinephrine, epinephrine and dopamine), PAH and
inulin. Blood samples for measurement of catecholamines, PAH and inulin were
centrifuged at 4° C for 10 min at 1500 g, immediately after sampling, and stored
deep-frozen before assay. The other blood samples were sent to the routine hospi-
tal laboratory for direct assay. Biophysical measurements included MAP, heart
rate (HR), FBF and various echocardiographic variables.
Methods
Both during the infusion of PAH and inulin and at the time of the echocardio-
graphic measurements, BP and HR were measured in the left arm using a semi-
automatic oscillometric device (Dinamap Vital Signs Monitor 1846, Critikon,
Tampa, FL, USA).
FBF was determined in the left forearm using ECG-triggered strain-gauge venous
occlusion plethysmography, a technique described in detail elsewhere **. In short,
the cuff for venous occlusion was placed just above the elbow. A mercury strain-
gauge was placed around the arm, 3-5 cm distal to the lateral humeral epicondyl.
The hand circulation was stopped by inflating a wrist cuff to suprasystolic pressure
starting one minute before each FBF measurement. Hence, FBF represents pre-
dominantly muscle blood flow "'. FBF was measured over a period of four min-
utes. The mean of the last two minutes was used for calculations. A flow curve
encompassed the time interval of five heart beats, during which venous occlusion
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(50 mmHg) was applied over three heart beats. Thus, we measured on average 12
inflow curves/min. Forearm vascular resistance (FVR, in mmHg/ml/dl/min) was
defined as the quotient of MAP and FBF.
Renal hemodynamics, i.e. ERPF and GFR, were assessed as the infusion clearance
of PAH (PAH: aminohippurate sodium; MSD, West Point, PA, U.S.A.) and inu-
lin (Inutest, Laevosan Gesellschaft, Linz, Austria), respectively. After the bolus in-
jection, a continuous infusion was initiated using a syringe pump (Terumo
SYC-521, Terumo Corporation, Tokyo, Japan) ^ . Blood was sampled, once be-
fore the bolus injection (blanks) and three times after an equilibration period of
120 min, in heparinized glass tubes (Monoject, Sherwood Medical, St. Louis,
MO, U.S.). Blood samples were immediately centrifuged at 4 °C for 10 min at
1500 ^ and plasma stored deep-frozen prior to assay. Both PAH and inulin were
measured as described elsewhere 85,86 The infusion clearances of PAH and inulin
were calculated by dividing the product of infusion rate and infusate concentra-
tion by the mean of plasma PAH and -inulin concentration after subtraction of
the blanks, respectively. We calculated RBF and renal vascular resistance (RVR)
using the formulas: RBF = ERPF/(l-hematocrit) in ml/min and RVR =
(MAP/RBF) x 80,000 in dyn.s/cm^. The filtration fraction (FF) was obtained by
taking the ratio of the inulin clearance (GFR) and the ERPF. Renal fraction (RF)
was calculated by taking die ratio of RBF and CO.
Echocardiographic measurements were performed in semi-left lateral position.
The echocardiographic recordings were made with a cross-sectional, phased-array
echocardiographic Doppler system (Hewlett-Packard Sonos 500 and 1000). This
system utilizes a 2.5 MHz phased array transducer and a 1.9 MHz independent
continuous-wave transducer. Data were registered on a strip chart recorder at a pa-
per speed of 25 mm/s for M-mode and at 50 mm/s for Doppler measurements.
CO was calculated according to the formula: CO = stroke volume (SV) x HR. To
determine SV, flow was measured across the aortic valve. Aortic velocities were re-
corded by means of the apical approach. A careful search for the maximal velocity
was made. No angle correction was used to standardize measurements. The area
under the velocity curve (aortic velocity integral) was recorded on disc. The mean
aortic velocity integral was calculated from five consecutive ejections. The diame-
ter of the aortic valve was measured off-line at the aortic orifice during systole with
the M-mode echocardiographic aortic valve separation. SV was calculated as aortic
area x aortic velocity integral. The aortic area was calculated as I4n(aortic diame-
ter)^. HR was derived from the averaged duration of five consecutive R-R intervals
on the ECG. Total peripheral vascular resistance (TPR) was calculated by using
the formula TPR (dyn.s/cm^) = MAP (mmHg) x 80 / CO (1/min). In this for-
mula, the MAP was calculated as the average of three recordings during measure-
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ment of the flow across the aortic valve using a semi-automatic oscillometric
device (Dinamap Vital Signs Monitor 1846, Critikon, Tampa, FL, USA).
Serum 17P-estradiol and progesterone were determined using reagent kids of
DPC (DPC, Los Angeles, Cal.). These assays are based on solid-phase radioimmu-
noassays using coated tube technology. Sensitivity of the assays are 0.035 and 0.15
nmol/1, respectively. For these two substances precision is better than 5%. Norepi-
nephrine (intra-assay CV 4.5%, inter-assay CV 8.1%), epinephrine (intra-assay
CV4.1%, inter-assay CV 8.6%) and dopamine (intra-assay CV 3.9%, inter-assay
CV 7.1%) were assessed by a sensitive fluorimetric method, in which catechola-
mines are concentrated from plasma by liquid-liquid extraction and derivatized
with a selective fluorescent agent prior to chromatography "^. For each substance,
all samples from the same individual were assayed in a single run.
•p Statistical analysis
f Only ovulatory cycles were included for analysis of the differences between LP and
E FP, whereas all the cycles were included for analysis of differences between the
g FP's. A menstrual cycle was considered ovulatory when the mid-luteal serum pro-
| gesterone concentration exceeded 15 nmol/1 *'.
H Differences between LP and FP in each cycle (low and high-salt diet, n = 12 and
* 14 resp.), and in the FP between the high-salt - and low-salt diet cycles (n = 25)
"I were analyzed by the Wilcoxon Matched-Pairs Signed-Ranks Test. Correlations
5 between concomitantly measured variables or between differences in potentially
• related variables were tested by Spearman's rank correlation analysis. In the com-
f parisons a p-value of less than 5% was considered statistically significant.We calculated detectable changes in the mean of variables (n = 14, CC = 0.05 and P
= 0.10), assuming a normal distribution of the data. The minimum detectable
changes were 3.2%, 10.1%, 10.7%, 4.7%, 10.7%, 15.6% and 25.0% for the
MAP, CO, TPR, GFR, ERPF, RVR and FBF, respectively.
RESULTS
Twenty-five of the 29 subjects completed all measurements (two menstrual cy-
cles), whereas four subjects completed the two measurements in a single menstrual
cycle (three low-salt menstrual cycles, one high-salt menstrual cycle). Four of the
in total 54 menstrual cycles (one low-salt menstrual cycle, three high-salt men-
strual cycles) were excluded from analysis because of irregular blood loss. Fourteen
of the 23 (61%) high-salt menstrual cycles and twelve of the 27 (44%) low-salt
menstrual cycles were ovulatory.
During the FP of high-salt menstrual cycles compared to the FP of low-salt men-
strual cycles (n = 25) the GFR and FF was consistently higher by 6% and 9% (me-
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Table 1A. Hormonal characteristics and sodium excretion of subjects (n = 12) during the FP
and LP of fow-sa/f. menstrua/ cyc/es.
FP LP Median difference
17p-estradiol (nmol/l)
Progesterone (nmol/l)
Norepinephrine (nmol/l)
Epinephrine (nmol/l)
Dopamine (nmol/l)
0.10(0.08-0.12)
2.1 (1.3-2.3)
0.63(0.54-1.10)
0.06 (0.04-0.09)
0.13(0.08-0.19)
Sodium excr. (mmol/24h) 56 (38-66)
0.32(0.27-0.36)**
25.3(20.4-45.0)**
0.65(0.61-0.79)
0.04 (0.02-0.06)
0.14(0.08-0.17)
46 (34-86)
+0.22 (+0.14 <->+0.28)
+22.7 (+18.6 o +47.3)
+0.00 (-0.19 <-» + 0.13)
-0.02 (-0.04 <-> +0.00)
+0.01 (-0.08 <-> +0.09)
+ 1.0<-27<->+42)
Values during the FP and LP are medians and interquartile ranges. Median differences (with
95% confidence interval) are listed in the final column. Changes in variables during the men-
strual cycle were evaluated using the Wilcoxon matched-pairs signed ranks test, * *p < 0.01,
***p < 0.001. FP, follicular phase; LP, luteal phase.
Table 1B. Hormonal characteristics and sodium excretion of subjects (n =14) during the FPand
FP LP Median difference
170-estradiol (nmol/l)
Progesterone (nmol/l)
Norepinephrine (nmol/l)
Epinephrine (nmol/l)
Dopamine (nmol/l)
0.10(0.06-0.12)
1.6(1.2-2.6)
0.47(0.41-0.77)
0.06 (0.05-0.09)
0.36(0.26-0.45)**
31.2(27.5-36.0)**
0.59 (0.45-0.76)
0.04 (0.03-0.09)
+0.28 (+0.13 <->+0.35)
+29.0 (+24.4 <-> +38.0)
+0.06 (-0.08 <-> +0.26)
-0.02 (-0.05 *-* +0.02)
0.13 (0.09-0.22) 0.14 (0.07-0.24) -0.03 (-0.06 *-> +0.07)
Sodium excr. (mmol/24h) 220 (172-279) 200 (156-244) -13 (-101 <->+66)
Values during the FP and LP are medians and interquartile ranges. Median differences (with
95% confidence interval) are listed in the final column. Changes in variables during the men-
strual cycle were evaluated using the Wilcoxon matched-pairs signed ranks test, **p < 0.01,
***p < 0.001. FP, follicular phase; LP, luteal phase.
dians), respectively, without concomitant change in ERPF, RVR and MAP. In
addition, in the high-salt cycles plasma concentration of norepinephrine was 26%
(median) lower than in the low-salt cycles.
Table 1 a and 1 b list the hormonal status and urinary sodium excretion of the sub-
jects during low-salt - (n = 12) and high-salt diet (n = 14), respectively. In the LP
relative to the FP, serum 17p-estradiol and progesterone had increased by a com-
parable margin in the low-salt - and high-salt menstrual cycle. Neither catechola-
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Table 2A. Systemic and renal hemodynamics, and forearm blood f low during the FP and LP of
fow-sa/f menstrua/ cyc/es (n = 12).
FP LP
MAP (mmHg) 79 (74-84) 78 (72-82)
Heart rate (beats/min) 57 (54-65) 61 (53-64)
Stroke volume (ml/min) 78.0(74.0-79.0) 80.0(75.0-82.0)
Cardiac output (l/min) 5.10(4.50-5.40) 5.30(4.40-5.60)
Median difference
-3 (-7 <-» +3)
+1 (-7 <-> +7)
+ 1.0 (-10.0 <-> +4.0)
-0.05 (-0.40 <-+ +0.90)
TPR (dyn.s/cm*) 1338(1226-1424) 1204(1067-1413) -60 (-352 <-> +171)
i
GFR(ml/min) 109(102-125) 111(103-127)
ERPF (ml/min) 508(454-565) 499(418-588)
Renal fraction (RBF/CO) 0.16(0.15-0.18) 0.16(0.13-0.18)
FF(GFR/ERPF) 0.21(0.20-0.25) 0.23(0.20-0.25)
+5 (-3 <-> +8)
-9 (-64 <-> +46)
+0.01 (-0.03 <->+0.01)
+0.01 (-0.01<-> +0.04)
RVR (dyn.s/cm*) 7767(7259-9279) 8015(7010-9615) -47 (-984 <-> +851)
!
FBF (ml/dl/min) 2.2(1.5-2.6) 1.8(1.3-2.0)
FVR (mmHg/ml/dl/min) 37.4(30.1-54.9) 43.0(36.2-58.2)
-0.4 (-0.7 «-> +0.4)
+5.8 (-20 <-> +18)
Values during the FP and LP are medians and interquartile ranges. Median differences (with
95% confidence interval) are listed in the final column. Changes in variables during the men-
strual cycle were evaluated using the Wilcoxon matched-pairs signed ranks test, *p < 0.05,
**p < 0.01. FP, follicular phase; LP, luteal phase; MAP, mean arterial pressure; TPR, total pe-
ripheral vascular resistance; GFR, glomerular filtration rate; ERPF, effective renal plasma flow;
FF, filtration fraction; RVR, renal vascular resistance; FBF, forearm blood flow; FVR, forearm
vascular resistance.
mines nor sodium excretion differed between LP and FP in the two different salt
cycles.
Table 2a and 2b list the medians (interquartile ranges) and the median differences
(95% CI) for systemic and renal hemodynamics, and forearm blood flow during
low-salt - (n = 12) and high-salt diet (n = 14), respectively. During the low-salt
menstrual cycles none of the variables measured had changed consistently. During
high-salt menstrual cycles HR was higher, TPR was lower and the MAP showed a
tendency to be lower (p = 0.06) in the LP. Cyclic changes in renal hemodynamics
consisted of a higher GFR and ERPF, and a lower RVR and FF. Finally, the RF
tended to be higher in the LP relative to the FP (p = 0.07).
In both low- and high-salt menstrual cycles, changes in TPR did neither correlate
with changes in serum progesterone concentration nor with the serum 17P-estra-
diol concentration or the ratio of serum progesterone to serum 17p-estradiol.
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Table 2B. Systemic and renal hemodynamics, and forearm blood flow during the FP and LP of
h/g/i-sa/t menstrua/ cyc/es (n = 14).
FP LP Median difference
MAP (mmHg) 82 (77-85) 78 (75-83)
Heart rate (beats/min) 59(55-61) 62(56-67)*
Stroke volume (ml/min) 76.0 (69.0-84.5) 78.0 (68.5-81.3)
Cardiac output (l/min) 4.70(4.50-5.25) 4.85(4.40-5.28)
TPR (dyn.s/cm*)
-0.5 (-4.0 <-> +5.0)
-0.05 (-0.5 <-> +0.6)
1336(1226-1453) 1320(1178-1441)* -71 (-179 *->-10)
GFR (ml/min) 117(109-127)
EFPF (ml/min) 492 (401-583)
Renal fraction (RBF/CO) 0.16 (0.13-0.19)
FF(GFR/ERPF) 0.24(0.21-0.28)
RVR (dyn.s/cm*) 8373 (7236-9885)
123(104-137)* +4(+1<->+13)
549(475-647)** +43 (+10 <-> +116)
0.18(0.15-0.20) +0.01 (-0.01 o+0.04)
0.22(0.21-0.24)* -0.02 (-0.05 <-» -0.01)
7562 (6352-8515)* -563 (-2613 <-» -50)
FBF (ml/dl/min) 2.1(1.4-2.5) 2.0(1.7-2.6)
FVR (mmHg/ml/dl/min) 40.1(31.2-57.3) 39.3(30.4-45.2)
+0.1 (-0.4 <->+0.9)
-0.2 (-14<->+8.9)
Values during the FP and LP are medians and interquartile ranges. Median differences (with
95% confidence interval) are listed in the final column. Changes in variables during the men-
strual cycle were evaluated using the Wilcoxon matched-pairs signed ranks test, *p < 0.05,
**p < 0.01. FP, follicular phase; LP, luteal phase; MAP, mean arterial pressure; TPR, total pe-
ripheral vascular resistance; GFR, glomerular filtration rate; ERPF, effective renal plasma flow;
FF, filtration fraction; RVR, renal vascular resistance; FBF, forearm blood flow; FVR, forearm
vascular resistance.
In neither low- nor high-salt menstrual cycles, the change in GFR correlated with
the change in serum progesterone -, serum 17(3-estradiol concentration, ERPF,
RVR or the ratio of serum progesterone to serum 17(3-estradiol. Also, we could
not demonstrate a correlation between changes in ERPF, RVR, RF on the one
hand and changes in serum progesterone -, serum 17(3-estradiol concentration, or
the ratio of serum progesterone to serum 17p-estradiol on the other hand. Neither
during low- nor during high-salt menstrual cycles, did changes in FF correlate
with changes in MAP. Finally, irrespective of the diet, the change in RBF did not
correlate with the change in CO.
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DISCUSSION
The objective of this study was to determine whether the general vascular relaxa-
tion, and renal vascular relaxation in particular, as they develop in the first weeks
of pregnancy, are also noticeable in the LP of the menstrual cycle. Our data sup-
ported this concept only partly. We found a decrease in TPR in the LP relative to
the FP. This decrease in TPR may not be evenly distributed over the systemic cir-
culation as a consistent fall in RVR was paralleled by inconsistent changes in FVR.
Interestingly this effect was only observed in subjects adhered to a high-salt diet.
The hormonal cyclicity in our study was expressed by a 0.22-0.28 nmol/1 higher
serum 17(}-estradiol in combination with a 22.7-29.0 nmol/1 higher serum pro-
gesterone in the LP as compared to the FP. The latter can be expected to have in-
"§. duced indirectly, through the well-known 0.3-0.5°C increase in core temperature,
"§ the higher HR and lower TPR in the LP. Animal studies ^ and in-vitro studies us-
js ing human placental arteries and veins ^ have shown that both progesterone ^'^*
E as well as 17[i-estradiol "" have vasodilating properties. To what extent these two
jj steroids act in concert in the LP of the menstrual cycle, to induce the observed de-
g crease in RVR and TPR is still obscure. We were unable to demonstrate a correla-
.B tion between changes in hormonal environment and changes in TPR, RVR and
jj RF. This may be related to the fact that vasorelaxation like the regulation of core
1 temperature, is not dose-dependent. The vaso-relaxant effect of the steroid hor-
5 mones was not discernible when the subjects used a salt-restricted diet. Switching
^ to a low-salt diet led to an increase in plasma norepinephrine. It is tempting to
t speculate that this causes an increased vascular tone, possibly, mediated by a de-
creased vascular filling state. In this concept, the cyclicity in renal hemodynamics
and TPR may have been overruled by this higher vascular tone. Possibly, opti-
mum hydration is a prerequisite for measurable vascular relaxation in the LP of the
menstrual cycle.
TPR was calculated by simultaneous non-invasive measurement of CO by Dop-
pler echocardiography and MAP by using an oscillometric device. Continuous-
wave Doppler measurement of flow in the aortic valve has been found to provide a
reliable and reproducible estimate for stroke volume 118,119 Kusumoto et al '^"
demonstrated that continuous-wave Doppler provides a reliable estimate of CO in
the study of serial changes in CO in response to various interventions. In the pres-
ent study CO had not changed by more than 10% within the menstrual cycle.
This observation agrees with the results reported by others using different meth-
ods '-'-'24. Only Chapman et al. '"^ demonstrated a 18% higher CO in the LP
compared to the FP using a comparable study protocol and methodology. It is
possible that a higher salt intake in the LP of the menstrual cycle as compared to
the FP, may have magnified the increase in CO in the latter study, e.g. by a larger
increase in ECFV and with it, preload. The relation between TPR and the men-
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strual cycle has also been studied previously '05.109,121 gy impedance cardiogra-
phy, it was demonstrated that the vascular tone in the LP was lower than in the
FP"^. However, this effect was only seen in response to stress. Lehtovirta et al. '^'
did not find cyclicity in TPR during the menstrual cycle. However, their study
group (n = 8) was too small to generate sufficient power to discern small changes in
TPR. They also compared the late FP with the LP, an approach that can be ex-
pected to reduce the differences in e.g. serum 17|3-estradiol concentration. Chap-
man et al. '"^ reported of a much greater cyclic effect on the TPR in the LP: 22%
lower compared to the FP, obviously, as a direct consequence of a much larger CO
in the LP of the menstrual cycle. The fact that the majority of women were initially
studied in the FP of the menstrual cycle might have increased their observed
change in TPR. Because both 17P-estradiol and progesterone can be held respon-
sible, at least in animal studies and in-vitro 78,79^  £>,. ,-he observed decrease in TPR,
we expected to find a correlation between the change in serum 17P-estradiol con-
centration, that in progesterone concentration and that in the ratio of serum pro-
gesterone to 17(3-estradiol in the LP on the one hand, and the change in TPR on
the other hand. The fact, that we were unable to find such correlations indicates
that the hemodynamic effects of fluctuations in endocrine environment during
the menstrual cycle do not follow a simple dose-response relationship.
To our knowledge, in only three studies the GFR and ERPF were studied together
in their relation with the menstrual cycle 11,12,109 j ^ , ^ , Q studies " ' ' ^ trend to-
wards an increased ERPF was noticed without a consistent change in FF, but the
changes were small and did not reach statistical significance. The latter was at least
in part caused by the relatively high variability of the methodology employed.
Only Chapman et al. ' ^ demonstrated a comparable increase in GFR and ERPF,
and thus without change in the FF, in the LP compared to the FP. In our study the
ERPF seemed to have increased by a larger fraction than the GFR thus giving rise
to a consistent fall in FF in the LP. It is possible that the salt-intake in the study by
Chapman and coworkers was higher in the LP relative to the FP, causing e.g. a
larger luteal GFR increase. On the other hand, the absolute differences are so small
that they may have been a result of random error and/or slightly different method-
ology. To reduce the variability in the measurements, induced by differences in
salt intake, we asked the subjects to adhere strictly to their salt diet. Due to a larger
percentage increase in ERPF than in GFR in the LP compared to the FP, we ob-
served a modest fall in FF. In this study neither the changes in GFR and ERPF
were correlated with each other during the menstrual cycle, nor did these changes
correlate with the change in sex steroids. So, it is not certain whether the GFR in-
crease in the LP is directly related to the observed increase in ERPF. Furthermore,
these data do not provide insight in the mechanism that leads to these renovascular
changes in die menstrual cycle. The concomitantly lower FF in the LP, suggests
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that the relaxation stimulus has a stronger dilatating effect on the efferent - than
on the afferent renal arterioles.
If systemic vascular relaxation in the LP would be evenly distributed over the vas-
cular bed, one would also expect to find a higher blood flow in muscle tissue. We
did neither find a higher FBF nor a lower FVR in the LP. Although, the minimum
detectable change was large in our study (25%), similar observations have been re-
ported by others '2,93-96 Therefore, we feel that the latter result together with the
other data in this study, provide evidence for a selective vascular relaxation in the
LP of the menstrual cycle. The observed tendency of the RF to increase during
high-salt menstrual cycles supports this concept. The stimulus for such a selective
vaso-relaxation remains to be identified.
In conclusion, the present data show, in case of sufficient salt intake, a decrease in
"g, both TPR and RVR in combination with inconsistent changes in FVR in the LP
"g of the menstrual cycle. The increase in GFR in the LP is paralleled by an increase
£ in ERPF and a decrease in FF. Post-ovulatory vasodilation of efferent, more than
E afferent, renal arterioles could be responsible for the raised GFR. The hemody-
g namic changes induced by the endocrine environment of the LP of the menstrual
^ cycle are modified by salt intake, and mimic the hemodynamic adaptation to early
5 pregnancy.
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ABSTRACT
This study was designed to test the hypothesis that endogenous progesterone is
needed for the development of the hemodynamic changes in the luteal phase of
the menstrual cycle.
We measured in both luteal and follicular phase of the menstrual cycle, cardiac
output, blood pressure, glomerular filtration rate, effective renal plasma flow,
forearm blood flow, plasma volume and their regulatory neurohormones (renin-
angiotensin-aldosterone system and ANP). Measurements were performed while
the subjects used a standardized high-salt diet. A menstrual cycle was considered
E ovulatory when the mid-luteal serum progesterone concentration exceeded 15
>> nmol/1 and anovulatory when it was less than 15 nmol/1. Differences between lu-
1 teal phase and follicular phase in the menstrual cycle, as well as differences in cyclic
£ changes and baseline values (follicular phase) between groups (ovulatory and ano-
™ vulatory) were analyzed using non-parametric tests.
5 Under basal condition (follicular phase), only, serum 17(3-estradiol level was
tj higher in the ovulatory group as compared to that in the anovulatory group. The
S" ovulatory group differed from the anovulatory group by a rise in the luteal phase
<u relative to the follicular phase, in effective renal plasma flow and renal fraction,
2 and a fall in filtration fraction. Cyclic changes in systemic vascular resistance,
^ glomerular filtration rate, plasma volume and neurohormones were comparable in
£ both groups.
^ The results of this study suggest that the luteal fall in systemic vascular resistance
£ and the rise in glomerular filtration rate are primarily 17p-estradiol-mediated,
2 whereas, the luteal rise in effective renal plasma flow is a selective progesterone ef-
fect. Possibly, progesterone down-regulates the angiotensin ATI receptor in the
efferent arteriole of the glomerulus.
INTRODUCTION
In the luteal phase of the menstrual cycle (LP), renal and systemic vascular resis-
tance fall, while sodium and fluid retaining mechanisms are activated ' ^ . When
ovulation is followed by conception and implantation, these luteal changes be-
come more pronounced in the following weeks of pregnancy ' ^ . Neither the trig-
ger for the changes in the LP, nor the one giving rise to their post-implantation
amplification, have been identified. The LP differs from the follicular phase (FP)
by higher levels of progesterone and 17fJ-estradiol, steroids with known vasodilat-
ing properties ™""°. Whether these two steroids, alone or in combination, are di-
rectly responsible for the changes in hemodynamics during the LP, is unknown. It
is conceivable that the role of these two steroids is limited to the institution of a
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"luteal" endocrine environment, necessary for some other not (yet) identified
vasodilator substance to become activated. Disclosure of the mechanism responsi-
ble for the luteal changes can be expected to improve our insight in the subsequent
superimposed changes in early pregnancy.
The objective of the present study was to test the hypothesis that endogenous pro-
gesterone is needed for the development of the hemodynamic changes in the LP of
the menstrual cycle. To this end, we compared cyclic changes in systemic vascular
resistance, renal hemodynamics and volume homeostasis in anovulatory cycles
with those observed in ovulatory cycles. In a previous study we noted, that cyclic
changes in renal hemodynamics are largest when subjects are using a high-salt in-
take '^7. Therefore, we performed our measurements while the subjects used a
standardized high-salt diet.
MATERIALS AND METHODS
Subjects
Experiments were performed in 29 healthy volunteers (mean age: 22 ± 4 (SD)
years; mean body mass index: 22 ± 3 (SD) kg/m^) with a history of regular men-
strual cycles (29 ± 3 days). All participants gave written informed consent and the
study was approved by the hospital's medical ethics committee. The investigation
conformed with the principles outlined in the Declaration of Helsinki.
Protocol
Two measurements were performed in the menstrual cycle, once in the follicular
phase (FP), between the third - and seventh day, and once in the LP, between the
20th - and 24th day. The subjects used a high-sodium diet of 220 mmol/day.
They started the diet seven days before each measurement. They collected a 24-
hour urine sample for determination of sodium and creatinine contents the day
before each measurement. Compliance with the diet was assessed by the 24-hour
sodium excretion. Completeness of urine collections was verified by 24-hour cre-
atinine excretions. Measurements started at 8.00 a.m., after an overnight fast, and
ended at 1.00 p.m.. The subjects were asked not to smoke and not to drink bever-
ages containing caffeine or alcohol, and to drink water only, on the day of the
measurements. Experimental conditions were similar on both study days. All
measurements were performed with the subject in supine position and the arm un-
der investigation at heart level, after an acclimatization period of at least 30 min.
Forearm blood flow (FBF) and renal hemodynamics were measured in a
temperature-controlled room (25-26° C). Before the acclimatization period, a
20-gauge catheter was inserted into a vein of the right forearm for infusion of
para-aminohippurate sodium (PAH) and inulin (see renal hemodynamics). An-
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other 20-gauge catheter was inserted into a vein of the left forearm in order to take
blood samples. At least 20 min after insertion of the catheter blood samples were
drawn from the left catheter for measurement of hematocrit, osmolality, albumin,
progesterone, 17P-estradiol, active plasma renin concentration (APRC), angio-
tensin II (Angll), aldosterone (Aldo), atrial natriuretic peptide (ANP), PAH and
inulin.. Blood samples for measurement of APRC, Angll, Aldo, ANP, PAH, and
inulin were centrifuged at 4° C for 10 min at 1500 g, immediately after sampling,
and stored deep-frozen before assay. The other blood samples were sent to the hos-
pital laboratories for direct determination. Besides sampling, mean arterial pres-
sure (MAP), heart rate (HR), FBF were determined, followed by echo-
cardiography and measurement of plasma volume (PV).
Measurements
During the infusion of PAH and inulin, and at the time of echocardiographic
measurements, blood pressure and HR were measured in the left arm using a
semi-automatic oscillometric device (Dinamap Vital Signs Monitor 1846, Cri-
tikon, Tampa, FL, USA).
FBF was determined in the left forearm using ECG-triggered strain gauge venous
occlusion plethysmography, a technique described in detail elsewhere '*. In short,
the cuff for venous occlusion was placed just above the elbow. A mercury strain
gauge was placed around the arm, 3-5 cm distal to the lateral humeral epicondyl.
The hand circulation was stopped by inflating a wrist cuff to suprasystolic pressure
starting one minute before each FBF measurement. Hence, FBF represents pre-
dominantly muscle blood flow *'. FBF was measured over a period of four min-
utes. The mean of the last two minutes was used for calculations. A flow curve
encompassed the time interval of five heart beats, during which venous occlusion
(50 mmHg) was applied over three heart beats. Thus, we measured on average 12
inflow curves/min. Forearm vascular resistance (FVR, in mmHg/ml/dl/min) was
calculated by using the formula: MAP/FBF.
Renal hemodynamics, i.e. effective renal plasma flow (ERPF) and glomerular fil-
tration rate (GFR), were assessed from the clearance of PAH (PAH: aminohippu-
rate sodium; MSD, West Point, PA, U.S.A.; coefficient of variation (CV) 8%)
and inulin (Inutest, Laevosan Gesellschaft, Linz, Austria; CV 6%), respectively,
using the constant infusion method. After the bolus injection, a continuous infu-
sion was started using a syringe pump (Terumo SYC-521, Terumo Corporation,
Tokyo, Japan) ^ . Blood was sampled in heparinized glass tubes (Monoject, Sher-
wood Medical, St. Louis, MO, U.S.) once before the bolus injection (blanks) and,
after an equilibration period of 120 min, thrice at ten min intervals. Blood was
centrifuged at 4 °C for 10 min at 1500 £ directly after sampling. All plasma sam-
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pies were stored deep-frozen prior to assay. PAH and inulin were measured as de-
tailed elsewhere >^86_ The infusion clearances of PAH and inulin were calculated
by dividing the product of infusion rate and infusate concentration by the mean of
the three plasma PAH and - inulin concentrations, after subtraction of the blanks,
respectively. We calculated renal blood flow (RBF, in ml/min) and renal vascular
resistance (RVR, in dyn.s/cm^) using the formulas: ERPF/(1-Hematocrit) and
(MAP/RBF)x80000, respectively. The filtration fraction (FF) was obtained by
taking the ratio of the GFR and ERPF. Renal fraction (RF) was calculated by tak-
ing the ratio of RBF and cardiac output (see echocardiographic measurements).
All data were standardized for body-surface area.
Echocardiographic measurements, as described in detail elsewhere ' ^ , were per-
formed in semi-left lateral position after approximately five minutes of rest. The
echocardiographic recordings were made with a cross-sectional, phased array
echocardiographic Doppler system (Hewlett-Packard Sonos 500 and 1000). Car-
diac output (CO) was calculated according to the formula: CO = stroke volume
(SV) x heart rate (HR). To determine SV, flow was measured across the aortic
valve. SV was calculated as aortic area x aortic velocity integral. Total peripheral
vascular resistance (TPR) was calculated by using the formula TPR (dyn.s/cm') =
MAP (mmHg) x 80 / CO (1/min). In this formula, the MAP was calculated as the
average of three recordings during measurement of the flow across the aortic valve
using the semi-automatic oscillometric device. All data were standardized for
body-surface area.
Plasma volume (PV, CV 4.2%) was measured, at approximately the same time in
the morning, as follows "" . Five |lCi '^I-human albumin, dissolved in 1 ml sa-
line, was given intravenously at time zero (total body dose of irradiation = 0.04
mSv). Before the bolus injection and again after 10, 20 and 30 min, blood samples
(5ml) were drawn to determine the volume specific plasma radioactivity
(mCi/ml). The virtual volume specific plasma radioactivity at time zero was calcu-
lated by extrapolation using the three serially obtained volume specific plasma ra-
dioactivity data points after bolus injection. PV was obtained by dividing the total
injected radioactivity by the virtual volume specific plasma radioactivity at time
zero, corrected for blanks. To eliminate the impact of body fat on PV per kg body
weight, we calculated the body fat fraction ' ^ , in order to be able to express the
PV in ml/kg lean body mass.
Serum 17fj-estradiol and progesterone were determined using reagent kids of
DPC (DPC, Los Angeles, Cal.). These assays are based on solid-phase radioimmu-
noassays using coated tube technology. Sensitivity of the assays are 0.035 and 0.15
nmol/1, respectively.
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APRC was assessed by the IRMA-method (Nichols Institute Diagnostics, Wy-
chen, The Netherlands) with an intra-assay coefficient of variation (CV) of 2.9%
and an inter-assay CV of 7.6% ' '^. Angll was determined by radio-immunoassay
(RIA) following Ph Phenyl column extraction (Amersham Int. Amersham, UK;
intra-assay CV 4.6% and inter-assay CV 7.7%) ' ' 1 Aldo was assayed by means of
a solid-phase protein binding RIA (Diagnostic Products Corporation, LA, USA;
intra- and inter assay CV 4.3% and 6.7% resp.) "-\ ANP was measured by a com-
petitive protein-binding radio-immunoassay (Nichols Institute Diagnostics; in-
tra- and inter assay CV 7.0% and 12.9%, resp) following extraction of plasma over
Sep-Pak C18 columns ' " \ For each hormone, all samples from the same individ-
ual were assayed in a single run.
I Statistical analysis
-C
•o
c
A menstrual cycle was considered ovulatory when the mid-luteal serum progester-
one concentration exceeded 15 nmol/1 and anovulatory when it was less than 15
nmol/1.
Differences in cyclic changes and baseline values (FP) between the ovulatory - and
anovulatory group were analyzed by the Mann-Whitney-U Test. Differences be-
tween LP and FP in the menstrual cycle were analyzed by the Wilcoxon Matched-
Pairs Signed-Ranks Test. Correlations between potentially related variables were
tested by Spearman's rank correlation analysis. In the comparisons a p-value of less
than 5% was considered statistically significant.
RESULTS
Twenty-six subjects completed the two measurements in a high-salt menstrual cy-
cle. Four of these were excluded from analysis because of irregular blood loss.
Fourteen of the menstrual cycles were ovulatory, whereas eight were anovulatory.
Before testing differences in cyclic changes between ovulatory and anovulatory
subjects, we evaluated the inter-group differences for all variables under basal con-
ditions (FP). Only serum 17P-estradiol level was higher (p = 0.02) in the FP of the
ovulatory group as compared to that in the anovulatory group.
Table 1 lists the median values in the FP and the median differences (with 95%
confidence intervals) between both phases of the menstrual cycle, for sex steroids
and urinary sodium excretion in the ovulatory - and anovulatory group. Only the
change in serum progesterone was significantly greater (Fig. la, p < 0.001) in the
ovulatory group compared to the anovulatory group.
Medians of cyclic changes (with 95% CI) for central hemodynamics, renal vari-
ables and forearm blood flow in both groups are listed in Table 2. The ovulatory
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Table 1. Hormonal characteristics and sodium excretion of subjects during ovulatory and ano-
vulatory menstrual cycles.
17p-estradiol
(nmol/l)
Progesterone
(nmol/l)
Sodium excr.
(mmol/24h)
Ovulatory cycle (n = 14)
FP*
0.10
(0.06-0.12)
1.6
(1.2-2.6)
220
(172-279)
LP - FP *
+0.28**
(+0.13 <->+0.35)
+29.0**
(+24.4 <-» +38.0)
-13
(-101 «->+66)
Anovulatory cycle (n = 8)
FP*
0.07
(0.06-0.07)
1.9
(1.5-2.0)
192
(148-234)
LP - FP *
+0.21*
(+0.04 <-» +0.31)
+4.8*
(+2.9 <-> +9.0)
-32
(-118<->+44)
p-value *
p = 0.14
p < 0.001
p = 0.71
Medians and interquartile ranges of the FP \ and median differences (with 95% confidence
interval) between LP and FP * are listed. Changes in variables during the menstrual cycle were
evaluated using the Wilcoxon matched-pairs signed ranks test (*p < 0.05, **p <0.01). Differ-
ences in cyclic changes between ovulatory and anovulatory cycles were analyzed by the
Mann-Whitney-U test^. FP, follicular phase; LP, luteal phase; sodium excr., sodium excretion.
group differed from the anovulatory group by a rise in ERPF and RF, and a fall in
FF in the LP.
Cyclic changes in PV and neurohormones (Table 3) were comparable in both the
ovulatory - and anovulatory group. Most relevant variables are also shown in Figs.
2 and 3.
Neither in the ovulatory, nor in the anovulatory as well as in the total group,
changes in serum progesterone and 17(i-estradiol concentration correlated with
concomitant changes in any of the measured hemodynamic or neurohumoral
variables.
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Figure 1. Changes during ovulatory and anovulatory cycles in serum progesterone (nmol/l) (a,)
and serum 17-(3-estradiol (nmol/l) fty. * Wilcoxon Matched-Pairs Signed Ranks Test, ** Mann-
Whitney-U Test.
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Table 2. Central hemodynamic variables, renal hemodynamics and forearm blood flow of
subjects during ovulatory and anovulatory menstrual cycles.
Ovulatory cycle (n = 14) Anovulatory cycle (n = 8)
MAP
(mmHg)
HR
(beats/mi n)
SV
(ml/1.73m*)
CO
(l/min/1.73m*)
TPR
FPT
82
(77-85)
59
(55-61)
75.0
(70.8-81.9)
4.93
(4.72-5.19)
1328
LP - FP *
-1
+3*
(+1 <-> +7)
-0.5
(-4.6 <-> +4.9)
-0.05
FP '
76
(76-78)
55
(52-61)
76.0
(69.8-78.7)
4.42
(dyn.s/cm^/1,73m*) (1231-1492) (-
(-0.46 <-»+0.55) (4.10-4.89)
-69* 1484
0) (1336-1698)
LP - FP *
-1
(_7o+10)
+9*
(+1 o+16 )
-1.5
+0.30
(-0.57
-343*
(-917O-10)
2.41)
p-value '
p = 0.63
p = 0.10
p = 0.95
p = 0.25
p = 0.17
GFR
ERPF
(ml/min/1.73m*
RF
(RBF/CO)
FF
(GFR/ERPF)
RVR
120
(110-135)
490
(428-604)
0.16
(0.13-0.19)
0.24
(0.21-0.28)
8309
(dyn.s/cm71.73nrT) (7278-9588)
+5*
(+1 <->+11)
+50**
(+15 <-> +118)
+0.01
(-0.01 O+0.04)
-0.02*
(-0.05 <->-0.01)
-544*
(-2451 O-195)
110
(108-119)
500
(489-576)
0.17
(0.16-0.19)
0.21
(0.20-0.23)
8088
(7073-8401)
+7*
(+1 o + 1 7 )
-11
(-68 o +99)
-0.01
(-0.12 •-> +0.02)
+0.02
(-0.05 o +0.04)
+91.8
(-2093 o +1824)
p = 0.45
p = 0.07
p = 0.05
p = 0.02
p = 0.13
FBF
(ml/dl/min)
FVR
(mmHg/ml/dl/min)
2.1
(1.4-2.5)
40.1
(31.2-57.3)
+0.1
(-0.4 o +0.9)
-0.2
1.9
(1.3-2.1)
40.9
(37.9-58.4)
+0.8*
(+0.1 O+1.7)
-7.5
(-23.8O+20.1)
p = 0.09
p = 0.68
Medians and interquartile ranges of the FP \ and median differences (with 95% confidence in-
terval) between LP and FP * are listed. Changes in variables during the menstrual cycle were
evaluated using the Wilcoxon matched-pairs signed ranks test (*p < 0.05, **p < 0.01). Differ-
ences in cyclic changes between ovulatory and anovulatory cycles were analyzed by the
Mann-Whitney-U test^. FP, follicular phase; LP, luteal phase; MAP, mean arterial pressure; HR,
heart rate; SV, stroke volume; CO, cardiac output; TPR, total peripheral vascular resistance;
GFR, glomerular filtration rate; ERPF, effective renal plasma flow; RF, renal fraction; FF, filtra-
tion fraction; RVR, renal vascular resistance; FBF, forearm blood flow; FVR, forearm vascular re-
sistance.
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Figure 2. Changes during ovulatory and anovulatory cycles in systemic vascular resistance
(dyn.s/cm7i.73rrv) (a), glomerular fitration rate (ml/min/1.73m') (ity, effective renal plasma flow
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Mann-Whitney-U Test.
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Signed Ranks Test, ** Mann-Whitney-U Test.
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Table 3. Volume homeostasis and neurohormones of subjects during ovulatory and anovula-
tory menstrual cycles.
CWafcvy cyc/e (n =
FP' LP • FP'
Anovu/atory cyc/e (r> = 8)
FP' LP - FP' p-value -
PV
(ml/kg Ibm)
Ht
BMI
<kg/m*)
Osmolality
(mosm/kg)
Serum albumin
(g/l)
APRC
(mU/l)
Angll
(pmol/l)
Aldo
(nmol/l)
ANP
(pg/ml)
54.0
(48.7-57.1)
0.35
(0.33-0.37)
21.3
(19.8-24.4)
282
(278-284)
38.9
(36.8-40.2)
18.1
(10.7-24.6)
7.8
(6.1-10.8)
97.5
(10.0-193)
111.5
(52.8-147.0)
-0.8
(-3.5 M +3.9)
+0.00
(-0.02 <-»+0.01)
-0.1
(-0.4 <_, +0.5)
-5.0
(-9.0 <-> +2.0)
-1.0*
(-2.5 «-»-0.1)
+7 .5**
(+0.9 <->+14.8)
+1.3*
(+0.1 <-»+3.1)
+198**
<+3.0<->+313)
-32.0
(-50.0 «-> +12.0)
52.0
(48.5-54.2)
0.35
(0.34-0.36)
21.3
(20.3-22.7)
282
(280-283)
40.1
(38.9-41.3)
8.5
(6.3-14.7)
8.2
(7.4-9.4)
42.0
(10.0-119)
98.5
(88.0-120 7)
+0.9
(-2.3 *-> +4.9)
+0.01
(-0.04«-» +0.03)
-0.01
(-0.6<->+0.7)
-2.0
(-8.0 <-> +4.0)
-1.2
(-3.6 o +5.6)
+5.9*
(+0.5 <-> +32.1)
+1.1
(-3.0 <-» +4.4)
+ 105*
(+10.0 <-> +291)
-9.5
(-73.3 <-> +73.0)
p = 0.37
p = 0.74
p = 0.89
p = 0.27
p = 0.63
p = 0.49
p = 0.54
p = 0.26
p = 0.78
Medians and interquartile ranges of the FP *, and median differences (with 95% confidence
interval) between LP and FP * are listed. Changes in variables during the menstrual cycle were
evaluated using the Wilcoxon matched-pairs signed ranks test (*p< 0.05, **p<0.01). Differ-
ences in cyclic changes between ovulatory and anovulatory cycles were analyzed by the
Mann-Whitney-U test *. FP, follicular phase; LP, luteal phase; PV, plasma volume; Ibm, lean
body mass; Ht, hematocrit; BMI, body mass index; APRC, active plasma renin concentration;
Angll, plasma angiotensin II; Aldo, plasma aldosterone; ANP, atrial natriuretic peptide.
DISCUSSION
The objective of the present study was to determine the individual roles of proges-
terone and 17f$-estradiol in the hemodynamic changes observed during the men-
strual cycle. Cyclic central and peripheral hemodynamic changes in ovulatory
women were compared with those in anovulatory women. Because in our previous
reports '25.127^  ^g ^ l y observed cyclic hemodynamic changes in women on a
high-salt diet, all subjects were put on a diet containing 220 mmol of sodium per
day. Our data show that, except for a higher serum 17(3-estradiol in the ovulatory
group, follicular values of all variables in both groups were comparable. Of all the
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measured variables, only the cyclic changes in serum progesterone, ERPF, FF and
RF differed between the two groups. Although these differences between both
groups were small, their combination brings up for some interesting inferences.
In both groups the GFR was higher in the "LP" of the menstrual cycle, but only in
the ovulatory group this increase was paralleled by a rise in ERPF and RF, and a
fall in FF and RVR (Table 2 and Fig.2). Although, the behaviour of the renin-
angiotensin-aldosterone (RAA) system was comparable in both groups, the mag-
nitude of the cyclic changes was somewhat greater during ovulatory cycles than
during anovulatory cycles (Table 3 and Fig.3).
A tendency of the RAA-system to become more activated during ovulatory cycles
than during anovulatory cycles may be seen as a compensation for the natriuretic
effect of progesterone '3-15^ resulting in no detectable changes in PV and plasma
ANP levels in both types of cycles. Oparil et al. ^ described that, next to com-
_ petitive inhibition of aldosterone at the distal tubulus, the diuretic effect of pro-
• gesterone may be related to changes in renal hemodynamics. After intramuscular
=5 administration of progesterone in male subjects they observed an increase in
£ ERPF, a stable GFR and a decrease in FF. Theoretically, a lower FF will lead to a
ifr lower peritubular oncotic pressure and, hence, increased reabsorption of sodium
in rJif proximaJ rubuie. Ar a/jj' rare, our observations on cydr'c changes in reno vas-
cular dynamics in ovulatory cycles compared to anovulatory cycles, resemble those
reported by Oparil et al. ' ^ with respect to the renal effects of progesterone. It is
conceivable, that analogous to the situation in pregnancy, progesterone decreases
the sensitivity for Angll, a potent vasoconstrictor of the efferent arteriole, thereby
causing the above mentioned renal hemodynamic effects. Although this could ex-
plain the decrease in RVR, it does not sufficiently account for the rise in GFR.
However, it is not known to what extent the interplay between progesterone,
17p-estradiol and Angll modulates the ratio between vascular resistances of the af-
ferent and efferent arterioles. Interestingly, Kalenga and co-workers reported
down-regulation of the angiotensin ATI receptor in human trophoblast cells by
progesterone but not by 17(3-estradiol ' ^ . It is tempting to speculate that proges-
terone and not 17|i-estradiol also triggers down-regulation of the angiotensin
ATI receptor in the efferent arteriole of the glomerulus.
The lack of an increase in GFR in response to progesterone ' ^ together with our
observation of an increase in GFR also in anovulatory cycles suggests that the rise
in GFR is primarily estrogen-mediated. The fact that no correlation was found be-
tween changes in GFR and changes in serum 17p-estradiol indicate that the rela-
tionship between these two variables is probably complex.
In-vitro studies using human and animal arteries showed that both progesterone
alone and 17f$-estradiol alone can cause vascular relaxation "^fffl. w ^ observed
that the luteal decline in TPR in the ovulatory group and anovulatory group is
comparable. To our knowledge TPR has never been studied in vivo in human
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anovulatory menstrual cycles. It seems that in vivo, 17p-estradiol, and not proges-
terone, is the major mediator in causing menstrual cycle related vascular relaxa-
tion. The observed "luteal" increase in FBF during anovulatory cycles only, is
compatible with this concept.
In conclusion, except for a difference in cyclic change in serum progesterone,
ERPF, FF and RF, we did not find statistical significant differences in cyclic he-
modynamic changes between ovulatory and anovulatory menstrual cycles. Al-
though in many instances both steroids may act in concert in inducing the
hemodynamic changes with the menstrual cycle, the results of this study suggest
that the luteal fall in systemic vascular resistance and the rise in GFR are primarily
a 17P-estradiol effect, whereas, the luteal rise in ERPF is a selective progesterone
effect. Whether the latter is a consequence of progesterone induced down-
regulation of the angiotensin ATI receptor in the efferent arteriole of the glomeru-
lus, remains to be elucidated.
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ABSTRACT
O/^rfnv: The objective was to test the hypothesis that women with a recent his-
tory of preeclampsia have abnormalities in renal hemodynamics and volume
status.
5ft#/y D«/gw: We studied a group of 26 primiparous ex-preeclamptics (ex-PE
a group) and a group of 12 parous women with a history of uneventful pregnancies
g- (controls). At least four months post-partum we compared the following variables
•5 between these groups: effective renal plasma flow (ERPF), glomerular filtration
^ rate (GFR), plasma volume (PV) and plasma concentrations of active renin
S (APRC), angiotensin II (Angll), aldosterone (Aldo) and atrial natriuretic peptide
•| (ANP).
2 /fau/&; Both PV and ANP were lower in the ex-PE group. As compared with the
| controls, the ex-PE group also had a lower ERPF, a higher filtration fraction (FF)
-5 and a higher renal vascular resistance (RVR). Intergroup differences in APRC,
•° Angll and Aldo were small and inconsistent.
3 COWC/K '^OW: Women with a history of preeclampsia are relatively hypovolemic and
I tend to have lower effective renal plasma flow and higher renal vascular resistance
-• and filtration fraction than do controls. These findings support the hypothesis
| that otherwise healthy women with a history of preeclampsia show abnormalities
-^  in their volume status and renal hemodynamics, irrespective of their blood pres-
£ sure.
INTRODUCTION
Recent evidence suggests that endothelial cell dysfunction plays a key role in rJie
pathogenesis of preeclampsia, a clinical syndrome during the second half of preg-
nancy characterized by increased capillary permeability (edema, proteinuria),
vasoconstriction (hypertension, renal and liver dysfunction) and activation of the
clotting cascade (thrombocytopenia) 33,130 -p|^ events during the first half of
pregnancy that lead to both functional and morphologic abnormalities of the en-
dothelium, although still incompletely understood, are considered to be secon-
dary to placental ischemia, which in turn may be the consequence of poor
placentation ^ ' ^ .
Data from epidemiologic studies suggest that the cause of defective placentation is
multifactorial. Next to genetic ^ ' ^ and immunologic ^ ' ^ predispositions, there
seems to be an important role for vascular factors ^ . Support for vascular factors as
potential triggers for preeclampsia comes from the observation that the incidence
of preeclampsia is increased among women with chronic hypertension ^ or dia-
betes mellitus '^ .The relative importance of each of these potential causes of
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preeclampsia and their mutual relationship can only be determined by in-depth
exploration, either in the non-pregnant state or during the latent phase that pre-
cedes manifest disease. In this respect it was an important finding that among sub-
jects with a history of severe early-onset preeclampsia, in addition to chronic
hypertension, the prevalence of subclinical abnormalities in the clotting system
leading to thrombophilia was found to be substantially increased ^ .
Whether there is also a subgroup of women with latent cardiovascular dysfunction
who may be at risk for preeclampsia is unknown. Several years ago it was demon-
strated that healthy, normotensive subjects with an increased risk for development
of hypertension display abnormalities in their renal hemodynamics and renin-
angiotensin-aldosterone system ' ^ .
This study was therefore designed to test the hypothesis that symptom-free, appar-
ently healthy women with a history of preeclampsia have abnormalities in their re-
nal hemodynamics and volume status. To this end we compared the effective renal
plasma flow (ERPF), glomerular filtration rate (GFR), plasma volume (PV) and
the plasma concentrations of active renin (APRC), angiotensin II (Angll), al-
dosterone (Aldo) and atrial natriuretic peptide (ANP) between two groups of pa-
rous women with or without previous preeclampsia.
MATERIAL AND METHODS
Subjects
Experiments were performed in 26 primiparous women with a history of
preeclampsia ' (ex-PE group) and 12 subjects with a history of uneventful preg-
nancies (control group). Women with a history of preeelampsia were selected
from the outpatient departments of two tertiary referral centers (University Hos-
pital Maastricht and Sophia Hospital in Zwolle), whereas subjects from the con-
trol group were recruited by an advertisement in a local newspaper.
Contraindications for recruitment were lactation and the use of any medication.
Subjects' characteristics are listed in Table 1. All participants gave written in-
formed consent, and the study was approved by the hospital's medical ethics com-
mittee. Measurements were performed at least four months post partum (mean ±
SD of ex-PE - and control group were 7 ± 2 and 41 ± 35 months, respectively) and
in the midluteal phase of the menstrual cycle.
Protocol
All subjects were asked to adhere to their usual dietary regimen in the days before
die study. They collected a 24-hour urine sample for determination of sodium ex-
cretion on the day before the study. All measurements were performed in the
morning on two consecutive days. Data acquisition was started after an acclimati-
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zation period of at least 30 minutes with the subject in sitting (first day) or supine
(second day) position. The participants were asked not to eat, smoke, or drink, ex-
cept for water, during a period often hours before and during the measurements.
PV was measured on the first day of the study, and ERPF, GFR, plasma concen-
trations of ANP, APRC, Angll and Aldo were determined on die second day.
Measurements
PV (ml/kg body mass) was assessed with the iodine 125-labeled albumin tech-
nique with a coefficient of variation (CV) of 4.2%. A five (iCi dose of human albu-
min labeled with iodine 125, dissolved in 1 ml saline solution, was given
intravenously (total body dose of irradiation 0.04 mSv). After 10, 20 and 30 min,
blood samples (5ml) were withdrawn to determine the volume-specific plasma ra-
dioactivity (mCi/ml). The virtual volume-specific plasma radioactivity at the time
of bolus injection was calculated by extrapolation from the sequentially obtained
volume-specific plasma radioactivity data determined in the three consecutive
plasma samples. PV was obtained by dividing the total injected radioactivity by
the virtual volume-specific plasma radioactivity at the time of bolus injection.To
eliminate the impact of body fat on PV per kg body weight we calculated the body
fat fraction ' ^ to express the PV in ml/kg of lean body mass as well.
Renal hemodynamic values (ERPF and GFR) were derived from the plasma clear-
ances (continuous infusion method) of PAH (CV 8%) and inulin (CV 6%), re-
spectively ' \ During the infusion of PAH and inulin, mean arterial pressure
(MAP), systolic blood pressure (SBP), diastolic blood pressure (DBP) and heart
rate (HR) were measured in the opposite arm with a semi-automatic oscillometric
device (Dinamap Vital Signs Monitor 1846, Critikon, Tampa, FL, USA). The
measurements during the last 30 minutes of the two-hour equilibration period
were taken to calculate the average MAP, SBP, DBP and HR. Renal blood flow
(RBF in ml/min) and renal vascular resistance (RVR in dyn.s/cm'') were calcu-
lated by the formulas ERPF/(l-hematocrit) and (MAP/RBF) x 80,000, respec-
tively. Filtration fraction (FF) was obtained by taking the ratio of GFR and ERPF.
All measurements were standardized for body-surface area.
APRC was assessed by the IRMA-method (Nichols Institute Diagnostics, Wy-
chen, The Netherlands), with an intra-assay CV of 2.9% and an interassay CV of
7.6% "^. Angll was determined by radio-immunoassay (RIA) after ethanol ex-
traction (Nichols Institute Diagnostics; intra-assay CV 4.3% and interassay CV
7.5%) ' '^. Aldo was assayed by means of a solid-phase protein binding RIA (Diag-
nostic Products Corporation, La, USA; intra- and interassay CV 4.3% and 6.7%,
resp.) " \ ANP was measured by a competitive protein-binding RIA (Nichols In-
stitute Diagnostics; intra-assay and interassay CV 7.0% and 12.9%, resp.) after
extraction of plasma over Sep-Pak C18 columns ' " \
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Statistical analysis
Before analysis the distribution of all variables was tested for normality by means
of the Kolmogorov-Smirnov test. Because all variables were normally distributed,
we chose to analyze differences between groups by the Student-t test. An exception
was made for APRC, Angll and Aldo. Because we found in some cases levels that
were below the detection limit for these variables, the Mann-Whitney-U test was
used to analyze hormonal differences between groups. Differences in frequencies
between groups were evaluated by the Fisher exact test. Correlations between po-
tentially related variables were tested by Spearman's rank correlation analysis. In
die comparisons a p-value of less than 5% was considered statistically significant.
RESULTS
On average, MAP was higher in the ex-PE group than in the controls (p < 0.01;
Table 1). Data for renal hemodynamics, PV and plasma concentrations of ANP
are listed in Table 2; plasma concentrations of APRC, Angll and Aldo are de-
picted in Table 3. Compared with the control group, ERPF was significantly
lower, and FF and RVR were significantly higher in the ex-PE group. GFR did not
differ significantly between die two groups. Both PV and plasma concentrations
of ANP were significantly lower in the ex-PE group than in the control group. Be-
cause no difference in hematocrit between the groups was found, blood volume
was also lower in the ex-PE group. There were no significant differences between
the ex-PE group and the control group with respect to the renin-angiotensin-
aldosterone system.
Because differences in variables between groups could be related to differences in
duration of the postpartum period, age and MAP, we also calculated possible cor-
relations. Within the ex-PE group no correlation was found between PV (Fig 1),
ANP, ERPF or APRC and the duration of the postpartum period. ERPF was in-
versely related to age in the ex-PE patients (r = -0.41, p = 0.04) but not in the con-
trols. PV, ANP and APRC were not related to age in either group. APRC was
inversely correlated with MAP (r = -0.41, p = 0.04) and with PV (ml/kg lean body
mass; r = -0.52, p = 0.01) in ex-PE patients only. When tested in a stepwise multi-
ple regression model, only PV remained as a significant determinant of APRC.
There were no statistically significant correlations between PV, ANP or ERPF and
MAP in either group, nor were there significant correlates between PV, ANP or
ERPF and gestational age at delivery in the ex-PE group.
To be able to perform a post-hoc comparison between a normotensive, ex-PE sub-
group (ex-PE, normotensive) and the controls, we selected those patients (n = 16)
who had a MAP below the mean + 2SD of that of the control group (< 96 mmHg).
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Table 1. Characteristics of both groups of subjects.*
characteristic Controls
(n=12)
Age (yr) 33 ± 2
Primiparity (n) 3 (25)
Body mass index (kgW) 22 ± 4
BMI > 26 k g W (n) 1 (8)
GA at delivery (n < 32 wk) 0
HELLP (n) 0
IUGR(n<P,o) 0
SBP(mmHg) 112 ± 8
DBP (mmHg) 66 ± 9
DBP > 90 mmHg (n) 0
MAP (mmHg) 82 ± 7
Heart rate (beats/min) 67 ±11
Urinary sodium (mmol/24 hr) 139 ± 40
Ex-preeclamptics
(n = 26)
29 ±4*
26(100)^
24 ± 3
7(27)
13(50)
20 (77)
12(46)
79 ±14*
3(12)
94 ±13*
64 ± 8
138 ±42
* Data are either listed as means ± SD or as absolute numbers with percentage between pa-
renthesis. * p < 0.05, * p < 0.01, for the comparisons with controls (Student-t test). * p < 0.05
for the comparisons with controls (Fisher exact probability test).
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Figure 1. Scatterplot illustrating the lack of correlation between plasma volume (ml/kg of lean
body mass) and duration of postpartum period (months) in 24 ex-PE subjects. In two of the 26 ex-
PE subjects enrolled we could not measure plasma volume for logistic reasons.
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Table 2. Characteristics for renal function and volume status in both groups of subjects
(means ± SD).
Ex-preeclamptics
(n = 26)
482 ± 88'
134 ± 19
0.28 ± 0.04*
9981 ± 2468^
36 ± 4*
52 ± 5*
38 ± 19*
0.38 ± 0.02
* p < 0.05, * p < 0.01, * p < 0.001 for the comparisons with controls (Student-t test).
Characteristic
Effective renal plasma flow
(ml/min/1.73 m*)
Glomerular filtration rate
(ml/min/1.73 m*)
Filtration fraction
(GFR/ERPF)
Renal vascular resistance
(dyn.s/cm^)
Plasma volume
(ml/kg)
Plasma volume
(ml/kg lean body mass)
Atrial natriuretic peptide
(pg/ml)
Hematocrit
Controls
(n = 12)
553 ± 67
121 ± 21
0.22 ± 0.03
7490 ± 868
40 ± 3
55 ± 3
68 ± 26
0.38 ± 0.02
Table 3. Characteristics of the renin-angiotensin-aldosterone system in both groups of sub-
jects (medians and interquartile ranges).
Characteristic Controls
(n = 12)
Ex-preeclamptics
(n = 26)
Active plasma renin concentration (mU/l) 16.2 (9.7-19.7) 16.5 (10.8-22.2)
Plasma angiotensin II (pmol/l) 10.9(10.5-14.0) 11.3(6.7-16.8)
Plasma aldosterone (pmol/l) 0.17 (0.11 -0.21) 0.18 (0.11 -0.29)
* p < 0.05 for the comparisons with controls (Mann-Whitney U test).
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Figure 2. Differences (%) from controls in plasma volume (PV), atrial natriuretic peptide (ANP), ef-
fective renal plasma flow (ERPF), glomerular filtration rate (GFR), filtration fraction (FF), renal vas-
cular resistance (RVR), active plasma renin concentration (APRC) and plasma aldosterone (Aldo).
* P < 0.05, t P < 0.01, * P < 0.001 for the comparisons with controls (Student-t test).
The MAP of this normotensive ex-PE group (86 mmHg) was comparable with
the MAP of the controls (82 mmHg). The relevant variables are shown in Fig 2.
The lower ERPF in the normotensive ex-PE group just failed to reach statistical
significance when compared with controls (504 vs. 553 ml/min/1.73 m^, p =
0.07). GFR, FF and RVR, on the other hand, were significantly higher in the nor-
motensive ex-PE group than in the control group. Both PV and plasma ANP con-
centration were significantly lower in the normotensive ex-PE group than in the
control group. Plasma concentrations of APRC, Angll and Aldo did not differ be-
tween the normotensive ex-PE group and the control group.
COMMENT
It is still common practice to subdivide preeclampsia into a "superimposed" and a
"pure" phenotype, depending on whether the patient with preeclampia had pre-
existing hypertension '. However, there is increasing evidence to support the view
that the concept of "pure" preeclampsia must be abandoned. For instance the re-
cent discovery of thrombophilia, associated with latent abnormalities in hemosta-
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sis, in more than half of the women with a history of severe early-onset
preeclampsia indicates that many such patients with allegedly "pure" preeclampsia
in fact have other (subclinical) abnormalities ^ . The objective of this study was to
examine ex-preeclamptic women for latent abnormalities in volume status and re-
nal hemodynamics.
Renal biopsy studies in patients with preeclampsia have shown that merely 24% of
multiparous women, as opposed to 76% of primiparous women, have glomerular
endotheliosis, the histological hallmark of preeclampsia, as the only lesion ' H Wg
therefore included in our study only primiparous women with a history of
preeclampsia, as defined by the US National Institutes of Health Working Group
on Hypertension in Pregnancy '.
Our data show that even several months after delivery the PV of the ex-PE group
was 10% lower than that of a control group. Moreover, compared with the control
group, ERPF was lower and FF and RVR were higher in the ex-PE group.
In general, it is advisable to standardize dietary sodium intake in studies on renal
hemodynamics or the renin-angiotensin-aldosterone system. For practical reasons
food intake of the subjects in this study was not standardized, but all participants
were asked to refrain from excessive salt intake and to adhere to their usual dietary
regimen on the days before the study. Although not ideal, this practice resulted in
comparable 24-hour urinary sodium excretions in the two groups. We are there-
fore quite confident that the observed differences in renal hemodynamics between
the two groups are genuine.
Because we found an inverse correlation (r = -0.41) between ERPF and age in the
ex-PE group, a possible bias in the comparisons could be different mean ages of
the subjects in the groups under investigation. However, the potential effect of the
four years' difference in mean age between the subjects of the ex-PE group and the
control group is likely to be small. In addition, had the ex-PE group been four
years older, the difference in ERPF would have been even greater. It is therefore
most likely that ERPF is indeed lower in patients with a history of preeclampsia.
Likewise, FF and RVR are higher in this group of patients. Although this observa-
tional study was not designed to explore the underlying mechanism of these
changes, one could speculate that a decreased circulatory volume in ex-
preeclamptics might have caused the lower renal blood flow.
In patients with essential hypertension or in people at risk for the development of
hypertension, abnormal renal hemodynamics such as those found in this study are
usually associated with a suppressed renin-angiotensin-aldosterone system ' ^ . In
our study, however, we could not find significant differences in APRC, Angll or
Aldo between the ex-PE group and the control group. Yet APRC was inversely re-
lated to PV in ex-PE patients, indicating that in this group some stimulation of
renin occurred as a result of hypovolemia. However, any stimulating effect on the
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renin-angiotensin-aldosterone system was probably counterbalanced by concur-
rent suppression of renin as a result of higher blood pressure.
The International Committee for Standardization in Haematology (ICSH)
stated, in its report about recommended methods for measurements of red blood
cell volume and PV, that PV in healthy subjects measured by the radioiodine-
labeled albumin dilution technique amounts approximately 40 ml/kg in both
sexes ^ . In fact, we found exactly the same value in our control population.
Nevertheless, because the correlation of PV is closer with lean body mass than
with body weight, we expressed our PV data not only as ml/kg of body weight
but also as ml/kg of lean body mass '^-\ With both methods we obtained simi-
3 lar results, a significantly lower PV in the ex-PE group. The data therefore
« strongly suggest that women with a history of preeclampsia are unable to main-
|j tain a normal PV, at least during the first year after delivery.
| Although it is widely acknowledged that preeclampsia resolves soon after delivery,
•g diis study does not rule out the possibility that the observed changes in renal he-
"g modynamics and volume status are a result of preeclampsia. In other words, the
g syndrome itself may cause permanent structural damage to the vasculature, in-
| eluding that of the kidney ' ^ \ It is also possible that recovery takes more than four
•8" months. However, the lack of a relationship between the length of the recovery
I time post partum and the severity of the observed abnormalities makes the latter
•s explanation less likely. Although ideally one would perform a prospective study to
J rule out these theoretic possibilities, the low incidence of preeclampsia in nullipa-
^ rous makes such a study practically difficult to execute.
4 In our opinion the so-called "pure" phenotype of preeclampsia is best evaluated in
.2 a direct comparison with a demographically similar control group matched for
blood pressure. Because this could only be done in a prospective study design,
which for obvious reasons is not feasible, we chose to analyze our data by defining
a "pure" preeclampsia group (normotensive ex-PE group) with a MAP that fell
within the mean ± 2SD of that of the control group. We decided not to split up
the ex-PE group into subgroups on the basis of the severity of the syndrome be-
cause there was no correlation between gestational age at delivery (which is gener-
ally considered to reflect the severity of the syndrome) and any of the measured
variables. In the normotensive ex-PE group PV was again 10% lower than in con-
trols, a statistically significant difference. The data on renal hemodynamics took
an intermediate position between the control group and the ex-PE group with
higher pressures. Still, even in the normotensive ex-PE group, GFR, FF and RVR
were significantly increased with respect to these variables in the control group
(Fig 2). Likewise, ANP was significantly reduced in the normotensive ex-PE
group; again there were no differences with respect to APRC, Angll and Aldo.
If we assume that the observed changes in volume status and renal hemodynamics
precede the development of preeclampsia, it is tempting to speculate about the ex-
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istence of a group of patients with subclinical vascular diseases that have relative
hypovolemia in common. Because of their relatively low blood volume or latent
vascular abnormalities, the adaptive response of this group to pregnancy may dif-
fer from that seen in healthy women. The physiologic drop in vascular tone during
the first trimester '-^ could be a stressful event for these subjects because the com-
pensatory mobilization of blood from the venous compartment to meet the higher
demands for venous return may be inadequate. This in turn may trigger a redistri-
bution of cardiac output at the expense of the implantation site. In this respect the
recently observed state of sympathetic overactiviry in preeciamptics seems to be
consistent with this thought ^ . Instead of displaying vascular relaxation in com-
bination with a compensator)' rise in circulatory volume during the first trimester,
these subjects could respond to the early pregnancy-related vasorelaxing stimulus
either by a redistribution of the cardiac output away from the uterus or by an im-
paired vascular relaxation. Both phenomena would lead to a relatively hypoper-
fused implantation site, causing defective trophoblast development and thus
initiating the chain of events eventually culminating into placental ischemia. Pla-
cental ischemia indeed does play a key role in the pathogenesis of preeclampsia.
On the basis of our findings of a reduced PV and suppressed levels of ANP, we de-
termined that women with a history of preeclampsia are relatively hypovolemic,
even after delivery. Compared with values from women with a history of uncom-
plicated pregnancies, their renal blood flow is lower and their filtration fraction
and renal vascular resistance are higher. These findings support the notion that
women with a history of preeclampsia have subclinical alterations in volume status
and renal hemodynamics, even when they are normotensive. Whether these
changes play an important role in the pathogenesis of preeclampsia remains to be
established.
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ABSTRACT
Among ex-preeclamptic (ex-PE) women the prevalence of hemodynamic and
clotting disorders is raised. In this study we tested the hypothesis that the normal
cyclicity in hemodynamics and renal function with the menstrual cycle, as seen in
healthy women, is preserved in ex-PE subjects irrespective of whether or not they
had an underlying hemodynamic or clotting disorder.
W e compared the hemodynamic and volume cyclicity during the menstrual cycle
in ex-PE women (n = 39) with that in normal parous controls (n = 10). T h e ex-
PE's were subdivided into women with hypertension ( H T , n = 10), women with a
thrombophilic disorder (TP, n = 17) and women without these abnormalities
•i (REST, n = 12). W e measured at least 5 months postpartum, once during the fol-
•g licular phase (FP, day 5 ± 2) and once during the luteal phase (LP, day 22 ± 2) of
" the menstrual cycle, the following variables: body weight and length, mean arterial
pressure, heart rate (HR), cardiac output (CO), plasma volume (PV), glomerular
filtration rate (GFR), effective renal plasma flow (ERPF), renal volume homeo-
static hormones, reproductive hormones and catecholamines. From the measured
data, we calculated body mass index (BMI), cardiac index (CI), left: ventricular
work, total peripheral (TPR) and renal vascular resistance (RVR), effective renal
blood flow (ERBF) and renal filtration fraction (FF).
HT differed from controls by a higher baseline (FP) value for CO, CI, LVW,
RVR, ANP and norepinephrine. REST differed from controls by a lower baseline
PV and a higher baseline CO and LVW. Women in the TP group were compara-
ble with respect to baseline hemodynamics and renal function, except for a higher
RVR. In controls, HR, PV, ERPF, ERBF, volume regulatory hormones and nore-
pinephrine in the FP had increased in the LP while the RVR and ANP had de-
creased. In the three ex-PE subgroups, this cyclic pattern with the menstrual cycle
was preserved for most of these parameters.
Although baseline hemodynamic and volume status in ex-preeclamptic women
differs from that in normal parous controls, its cyclic pattern with the menstrual
cycle is largely preserved.
INTRODUCTION
In healthy women, hemodynamics and volume homeostasis vary with the men-
strual cycle '2,139 j;hg available data provide indirect evidence for mild vasore-
laxation in the luteal phase (LP) relative to the follicular phase of the menstrual
cycle (FP). In this respect, although much less profound, the LP mimics the early
weeks of pregnancy when systemic vasorelaxation is large enough to induce a com-
pensatory rise in cardiac output (CO) together with mild hemodilution as a sign
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of volume expansion and activation of volume regulatory hormones ' ^ . In con-
trast, pregnancies complicated by severe fetal growth restriction (IUGR) and/or
preeclampsia (PE), are often preceded by defective development of these eariy-
pregnancy changes .
Epidemiologic studies indicate that disorders with a thrombophiiic phenotype or
hypertension predispose to PE 64,HO Recently, another PE subgroup has been de-
scribed in which plasma volume (PV) was found to be reduced as compared to
normal parous controls '^'. These findings suggest that PE has different causes.
The notion that hemodynamic adaptation in early preeciamptic pregnancy is de-
fective/insufficient raises the question whether hemodynamic and volume
cyclicity during the menstrual cycle in ex-preedamptic women is different from
that in women with past uneventful pregnancies.
The objective of the present study was to test the hypothesis that the cyclicity in
hemodynamic and volume variables during the menstrual cycle is different in ex-
PE women as compared to normal parous controls. To this end, we compared in
both phases of the menstrual period blood pressure, cardiac function, renal hemo-
dynamics, PV, neurohumoral status, between ex-PE women and normal parous
controls.
MATERIALS AND METHODS
Selection and patient characteristics
In this study 39 ovulating ex-preeclamptic non-diabetic Caucasian women and 10
normal parous controls were enrolled. Participants were at least 5 months postpar-
tum. Ex-PE women were recruited at the outpatient clinic at the postpartum
follow-up, whereas controls were recruited by advertisement. PE and hyperten-
sion were defined according to the criteria of the International Society for the
Study of Hypertension in Pregnancy (ISSHP) ' ^ . Therefore, hypertension was
defined as a mean systolic and/or a mean diastolic arterial blood pressure higher
than 140 mmHg or higher than 90 mmHg, respectively, using all of the Dinamap
recordings accumulated at the day of the experiment. All experiments were pre-
ceded by one week of standardized sodium intake (100 mmol sodium per day),
representing the mean sodium intake in our population. This required that all par-
ticipants consulted the hospital's dietitian, prior to study. Women's compliance
with the diet was assessed by measuring 24 hour sodium output on the day before
the experiment. None of the women used vitamins, oral contraceptives, antihy-
pertensive drugs, NSAID's or glucocorticosteroids in the two weeks prior to the
measurements. On separate days and after an overnight fast, participants were
tested for thrombophilia and hemodynamic/renal function. All participants gave
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written informed consent. The study was approved by the hospital's medical eth-
ics committee.
Experimental procedure
T&rom^o/^ /'/fV «T«7M'/I£. Anticardiolipin antibodies (ACA; IgM and IgG) were de-
termined spectrophotometrically by enzyme-linked immunoassay ' ^ . Lupus an-
ticoagulant (LA) was determined by mixing 1:1 patient and pooled normal plasma
after finding a prolonged partial thromboplastin time. Subsequently, a thrombo-
plastin dilution test was performed by measuring prothrombin time with progres-
sive diluted thromboplastin ' ^ . LA was considered to be present when all assays
were positive. The presence of ACA and/or LA was, when higher than 10 GPL for
•1 IgG ACL and 6 MPL for IgM ACL, considered to be indicative of the antiphos-
•o pholipid syndrome (APS).
Coagulation tests were performed after a flawless venapuncture. Blood was col-
lected in sodium citrate containing glass tubes. Plasma was prepared by two con-
secutive centrifugation steps, with the second one performed in an Eppendorf
centrifuge to eliminate platelets. Samples were stored at -80 °C prior to assay. Pro-
tein C activity was determined with Coamate protein C (Chromogenix, Molndal,
Sweden) ' ^ . The normal value of protein C according to the laboratory control
group is 70% to 130% and has an intra-assay and inter-assay CV of 3.3% and
4.7%, respectively. Total protein S antigen and free protein S were measured by
an enzyme- linked immunosorbent assay (ELISA) (DAKO, Glostrup, Denmark)
' ^ . The normal range of both total protein S antigen (intra-assay and inter-assay
CV of 5.1% and 5.7%) and free protein S (intra-assay and inter-assay CV 3.4%
and 3.6%) is 70% to 130% and 65% to 130%, respectively. Activated protein C
resistance (APCR) was quantified by a chromogenic APC-resistance assay ' ^ . The
chromogenic test fully matches DNA analysis for the factor V Leiden mutation
and has a normal range between 0% and 20% ' ^ . Antithrombin III activity
(ATIII) was assayed with chromogenic substrate S-2765 (Chromogenix, Molndal,
Sweden) ' ^ . The normal range of ATIII is 80% to 120%.
A methionine loading test was used to diagnose hyperhomocysteinemia (HHC).
Homocysteine was measured by high-performance liquid chromatography with
fluorescence detection "" . In our hands, this test has an intra- and inter-assay co-
efficient of variation (CV) of 3.9% and 5.9%, respectively. At 8:30 AM, the fast-
ing homocysteine concentration was determined. Six hours after an oral dose of
L-methionine (0.1 g/kg body weight), the postload homocysteine concentration
was assessed. During the test participants used a standard low-methionine break-
fast and lunch. Individuals were considered to have HHC when fasting and/or
post-load plasma homocysteine levels were more than 2 standard deviations (SD)
higher than the mean of the laboratory control group.
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j . Both in the FP (day 5 ± 2)
and LP (day 22 ± 2) of the menstrual cycle (random order), measurements were
performed under standardized environmental conditions in a temperature-
controlled room (25-26 °C) and with as minimal external disturbances as possible.
Participants did not drink caffeine- or alcohol-containing beverages and refrained
from smoking and eating for at least 10 hours before the experiment. The meas-
urement session started at 8:00 AM, with the insertion of a 20-gauge catheter into
a vein of the right forearm, to enable determination of renal function as detailed
below. A second catheter was inserted into a vein of the contralateral forearm for
sampling of blood. Throughout each measurement session, subjects were in su-
pine position on a comfortable bed. Arterial blood pressure and heart rate (HR)
were recorded repeatedly at two minutes interval by a semi-automatic oscillomet-
ric device (Dinamap Vital Signs Monitor 1846, Critikon, Tampa, FL, USA),
throughout the measurement session. Effective renal plasma flow (ERPF) and
glomerular filtration rate (GFR) were measured by continuous infusion of PAH
(PAH: para-aminohippurate sodium; MSD, West Point, PA, USA) and inulin
(Inutest, Laevosan Gesellschafr, Linz, Austria), respectively ^,151 PAH and inu-
lin, measured spectophotometrically, had an intra-assay- and inter-assay CV of
4.2% and 7.3%, and 4.5% and 8.1%, respectively. Renal hemodynamics were
corrected for body surface area (BSA) and expressed in ml.min"'. 1.73 m" .^ ERBF,
renal vascular resistance (RVR) and filtration fraction (FF) were calculated as fol-
lows:
At least two hours after the initiation of the PAH/inulin infusion, three blood
samples were taken for determination of inulin and PAH. In addition, blood was
collected for assay of active plasma renin concentration (APRC), angiotensin II
(Angll), aldosterone (Aldo), atrial natriuretic peptide (ANP), sex-hormones and
catecholamines. APRC was determined by an immunoradiometric assay tech-
nique (Nichols Institute Diagnostics, Wychen, The Netherlands) with an intra-
assay CV of 2.9% and an inter-assay CV of 7.6% ' '^. Angiotensin II (Angll) was
assayed by radio-immunoassay (RIA) following Phenyl column extraction (Amer-
sham Int, Amersham, UK) wirJi an intra-assay CV of 4.2% and an inter-assay CV
of 7.7% ' '*. Aldosterone was assessed by a solid-phase protein binding RIA (Diag-
nostic Products Corporation, LA, USA) with an intra-assay CV of 4.3% and an
inter-assay CV of 6.7% ' ^ . Atrial natriuretic peptide (ANP) was analyzed by ra-
dioimmunoassay (Nichols Institute Diagnostics, Wychen, The Netherlands) with
an intra-assay CV of 9% and inter-assay CV of 12% "<\ Norepinephrine (intra-
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assay CV 4.5%, inter-assay CV 8.1%), epinephrine (intra-assay CV 4.1%, inter-
assay CV 8.6%) and dopamine (intra-assay CV 3.9%, inter-assay CV 7.1%) were
assessed by HPLC after liquid-liquid extraction and derivatization with a selective
fluorescent agent "^. Serum 17P-estradiol and progesterone were determined
with a commercially available solid phase radioimmunoassay kit (DPC, Los Ange-
les, Cal, USA). Sensitivity of the latter assays are 0.035 and 0.15 nmol/1, respec-
tively. Ovulation was confirmed when mid-luteal serum progesterone exceeded
15 nmol/1 *'. Samples were collected on ice and centrifuged at 4 °C for 10 min at
1500 £ immediately after sampling. All samples were stored deep frozen (- 80 °C)
prior to assay.
Afftttxrfrawr o//>£w;wd w/«»if (TV9. After the procedure to quantify renal func-
•I t ion, PV was measured. Plasma vo lume (PV, intra-assay C V of 4 . 2 % ) was deter-
•o mined with the iodine 125-labeled albumin (^^I-HSA) indicator dilution
method and expressed in ml per kilogram (kg) lean body mass (LBM). The LBM
was calculated as specified elsewhere '^*. PV was obtained by dividing the total in-
jected radioactivity by the virtual volume-specific radioactivity at time zero ^5 .
The latter, which corresponds with the time of bolus injection, was obtained by
extrapolation using the specific activity per ml of plasma at 10, 20 and 30 minutes
after bolus injection.
£f/'c»f<zr^ /'o^ 7Vj/>/y to assess cardiac function was performed in semi-left lateral posi-
tion, after completion of the PV measurement and after 5 minutes of rest, using a
cross-sectional, phased array echocardiographic Doppler system (Hewlett-
Packard Sonos 2000 and 2500) ^ .
CO
C/
In this formula, HR was obtained by taking the mean of five consecutive R-R in-
tervals on the ECG. Stroke volume (SV) was calculated by multiplying the aortic
velocity integral and the aortic area. Aortic flow was measured across the aortic
valves from an apical approach. The average area under the aortic velocity curve
(aortic velocity integral) of five consecutive ejections was used to calculate SV.
Aortic valve diameter necessary for the calculation of the aortic area, was measured
off-line at the orifice during systole using M-mode. Total peripheral vascular resis-
tance (TPR) and TPR index (TPR/) were calculated as follows:
777? =
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Left ventricular work (LVW), defined as the energetic expense on blood imposed
by the left ventricle per unit of time was calculated using the formula:
The value used for MAP was obtained during the CO measurement and was cal-
culated as the mean of three consecutive recordings.
.Drfta awa/y«>. The allocation of an ex-PE woman to either the hypertensive (HT)
or the normotensive subgroup was based on whether or not she had hypertension.
If not, then she was allocated to the normotensive thrombophilic group (TP) or
the normotensive nonthrombophilic group (REST) based on whether she had a
thrombophilic disorder or not. Data are presented as means ± SD unless otherwise
stated. Differences between groups were tested with the Mann-Whitney-U test
along with Bonferroni correction. Differences within groups between the FP and
LP were evaluated by Wilcoxon matched-pairs signed-ranks test. Correlation,
when calculated, between concommitantly measured potentialy related variables,
were tested by Spearman's Rank correlation analysis. In the comparisons a p-value
less than 0.05 was considered statistically significant.
RESULTS
On the basis of the criteria mentioned above 10 of the 39 women were assigned to
the HT subgroup. Two women in this subgroup had been diagnosed as having hy-
pertension prior to the study. Among these hypertensive subjects, three were
found to have a thrombophilic disorder as well, all in conjunction with HHC. Of
the remaining 29 (normotensive) ex-PE subjects, 17 (44%) had one (n = 16) - or
more than one (n = 1) thrombophilic disorder(s). They were allocated to the TP
subgroup. The remaining 12 ex-PE subjects had neither hypertension nor throm-
bophilia. They were allocated to the REST subgroup. The demographic character-
istics of all participants subdivided over the various subgroups are listed in Table 1.
The subgroups did not differ with respect to age, height, parity and urinary so-
dium excretion. Ex-PE females in the REST subgroup had a higher BMI then the
controls. Obviously, MAP was higher in the HT subgroup as compared to con-
trols.
The specifics on the thrombophilic disorder in the TP subgroup and some HT
subjects are listed in Table 2. Among the 39 ex-preeclamptic participants 51%
(20/39) had at least one disorder associated with thrombophilia. In the subjects al-
located to the TP subgroup, APS and protein S deficiency were most common,
followed by HHC, APCR and protein C deficiency. All ex-PE women which were
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1Table 1. Demographic data from the 3 subgroups of ex-preeclamptics and the group of nor-
mal parous controls.
Sge (years)
Height (cm)
BMI (kg.m'*)
Parity (median with range)
MAP(mmHg)
Natriuresis (mmol.24 h'')
controls
(n=10)
31 ± 2
168 ± 3
22 ± 2
1 (1-2)
83 ± 8
108 ± 26
ex-preeclamptics
TP
(n=17)
31 ± 4
166 ± 7
24 ± 4
1 (1-3)
84 ± 8
97 ± 37
REST
(n = 12
29 ±
167 ±
28 ±
1 d-2)
88 ±
97 ±
)
3
5
5t
6
33
HT
(n =
33
166
22
10)
± 4
± 4
± 3
1 (1-4)
107
81
± 6T
± 23
Data are presented as means ±SD. If a value is followed by an arrow, this particular variable is
higher (t) or lower (I) than the one in the control group.
Table 2. Occurrence of the various subtypes of thrombophilic disorders in the thrombophilic
and hypertensive subgroups of ex-PE women.
Type of thrombophilic disorder
ACA/LA (Antiphospholipid syndrome)
Hyperhomocysteinemia
Protein C deficiency
Activated Protein C Resistance
Protein S deficiency
AT-III deficiency
TP(n = 17)
7(41%)
3(18%)
1 (6 %)
1 (6 %)
6 (35%)
-
HT(n=10)
-
3 (30%)
-
-
-
-
diagnosed as having APS were IgG serotypes. We did not identify women with
AT-III deficiency.
Table 3 lists the systemic hemodynamic data measured in this study, with those
from the FP being defined as baseline values. Baseline systemic hemodynamics in
the TP subgroup were comparable to those in the control group. Baseline MAP,
CO, CI and LVW were higher in the HT subgroup as compared to controls. In
the REST subgroup baseline values of CO and LVW were higher and PV lower as
compared to the control group. PV did not correlate with BMI in any of the sub-
groups. With respect to the cyclicity, luteal PV was found to have increased rela-
tive to value in the FP, both in controls and in all three ex-PE subgroups. The
mean rise in PV of the control group and the three ex-PE subgroups was found to
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TabiesrHemodynamic aataoDtainea in the FP ana UP oftne menstrual cycle,
controls ex-preeclamptics
"•I
1
MAP (mmHg)
HR (bpm)
SV (ml.beat"')
CO (Lmin'*)
CKLmin-Vm^)
TPR(x1O*)
(dyne.s.cm"^)
TPRj(xiO^)
(dyne.s.cm'^.m^)
LVW(xiO^)
(mmHg.L.min"')
PV(ml.kg')
FP
LP
FP
LP
FP
LP
FP
LP
FP
LP
FP
LP
FP
LP
FP
LP
FP
LP
(n =
83
82
60
65
74
69
4.6
4.6
2.7
2.7
1.4
1.5
2.4
2.5
30
31
55
62
: 1
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
0)
8
5
9
10*
8
6
0.4
0.7
0.2
0.3
0.2
0.2
0.4
0.2
4
6
4
8*
TP
(n =
84
84
62
65
78
80
5.3
5.5
3.1
3.2
1.3
1.2
2.2
2.1
35
35
52
57
= 17)
± 8
± 7
± 10
± 8*
± 10
± 11?
± 0.7
± 1.1
± 0.4
± 0.5?
± 0.2
± 0 .2 l
± 0.4
± 0 .4 l
± 7
± 9
± 3
± 7*
REST
(n =
88
85
67
67
72
76
5.5
5.6
3.0
3.1
1.3
1.3
2.4
2.3
39
40
45
48
= 12)
± 6
± 8
± 8
± 8
± 12
± 12
± 0.9?
± 1.1
± 0.5
± 0.6
± 0.2
± 0.2
± 0.4
± 0.3
± 10?
± 12?
± 4 l
± 6*4.
HT •
(n=10)
107± 6?
106± 11?
70 ± 10
70 ± 12
79 ± 11
78 ± 12
5.9 ± 0.6?
6.0 ± 0.5?
3.5 ± 0.4?
3.6 ± 0.4?
1.5 ± 0.2
1.4 ± 0.2
2.5 ± 0.3
2.4 ± 0.3
49 ± 7?
50 ± 6?
53 ± 5
59 ± 8*
Data are presented in mean ±SD. An arrow that follows a particular value indicates this vari-
able to be higher (?) or lower (4) than the one in the control group in the corresponding phase
of the menstrual cycle. The symbol * indicates the LP value in a particular subgroup to be dif-
ferent from that in the FP.
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Table 4. Renal hemodynamics as determined in the FP and LP of the menstrual cycle.
;' controls ex-preeclamptics
1
!
TP
(n =
115
119
17)
± 13
± 18
REST
(n =
114
122
12)
± 24
± 27*
HT
(n =
111
120
10)
± 10
± 18*
( n=10 )
GFR FP 125 ± 8
(ml.min"'. 1.73 m"*) LP 130 ± 12
ERPF FP 565 ± 77 495 ± 71 500 ± 98 480 ± 105
(ml.min "'.1.73 m'*) LP 596 ± 64* 516 ± 774. 519 ±111 557 ± 133*
ERBF FP 881 ± 127 777 ± 129 791 ± 144 770 ± 169
(ml.min''.1.73 m'*) LP 935 ± 105* 809 ± 132 820 ± 163 897 ± 205*
FP 7.2 ± 1.3 8.4 ± 1.6? 8.6 ± 1.5? 10.9±2.6?
(dyn.s.cm"*.1.73m"*) LP 6.7 ±0.9* 7.9 ±1.5 8.2 ±1.7 9.2 ±2.6*?
FF FP 0.22 ± 0 . 0 3 0 . 2 3 * 0 . 0 3 0.23 ± 0.02 0.24 ± 0.04
(GFR/ERPF) LP 0.22 ± 0 . 0 3 0.23 ± 0 . 0 3 0.24 ± 0.03 0.22 ± 0 . 0 5 *
Sodium excr.
(mmol.24h"')
FP 108 ± 26
LP 123 ± 32
97 ± 37
89 ± 394.
97 ± 33
92 ± 25
81
84
± 23
± 304.
Data are presented in mean ±SD. An arrow that follows a particular value indicates this vari-
able to be higher (?) or lower (4.) than the one in the control group in the corresponding phase
of the menstrual cycle. The symbol * indicates the LP value in a particular subgroup to be dif-
ferent from that in the FP.
be comparable. Luteal HR was consistently higher in the controls and in the TP
subgroup, but not in the REST - and HT subgroups. In neither group did any of
the other hemodynamic variables listed in Table 3 vary with the menstrual cycle.
The renal hemodynamic data are listed in Table 4. All baseline data points were
comparable between groups except for a higher RVR in all ex-PE subgroups rela-
tive to the controls. The cyclicity in renal hemodynamics differed between groups.
In the control group luteal ERPF and ERBF had increased and the RVR had de-
creased relative to the FP. In the HT subgroup these changes were supplemented
with a luteal rise in GFR and fall in FF relative to the FP. In the REST subgroup
only the luteal rise in GFR reached significance whereas in the TP subgroup none
of the renal variables had changed significantly between the FP and LP. In the HT
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Table 5. Endocrine variables as determined in the FP and LP of the menstrual cycle,
controls ex-preeclamptics
APRC
(mil l " ' )
TP REST HT
( n = 1 0 ) ( n = 1 7 ) (n = 12) ( n = 1 0 )
FP 13.7± 4.5 12.1 ± 6 . 9 14.0± 5.3 1 8 . 3 ± 9 . 4
LP 21.7± 7.3* 23.7± 11.6* 2 1 . 2 * 5.5* 25.9± 10.4*
Angll
(pmol.L"')
Aldo
(nmol.L"')
ANP
(ng .L"')
FP 8.7 ± 2.4 9.9 ± 3.7 10.2± 2.4 10.7± 3.7
LP 1 3 . 7 * 10.4* 12.9*5.1* 13.0± 4.3* 15.7± 6.0*
FP 85 ± 3 0 82 ± 23 107 ± 39 109 * 68
LP 203 ± 141* 233 ± 106* 285 * 175* 183 ± 105*
FP 93 ± 26
LP 84 ± 2 1 *
97 ± 34
77 ± 29*
105 ± 50
98 ± 31
141 ± 46T
126 ± 73*
Norepinephrine FP 0.63 ± 0.20 0.84 ± 0.47 0.86 ± 0.19 1.28 ± 0 . 6 4 ?
(nmol.L"') LP 1.02 ± 0.20* 1.25 ± 0.68* 1.01 ± 0 . 2 4 * 1.27 ± 0.85
Epinephrine
(nmol.L"')
FP 0.06 ± 0.04 0.06 ± 0.03 0.06 ± 0.03 0.10 ± 0.09
LP 0.05 ± 0.03 0.06 ± 0.03 0.07 ± 0.07 0.06 ± 0.05
Dopamine
(nmol.L"')
FP 0.21 ± 0 . 1 2 0.27± 0.13 0.18± 0.07 0.18± 0.09
LP 0.21 ± 0 . 1 0 0 . 2 2 ± 0 . 1 1 O.23±O.1O 0.19± 0.10
17p-Estradiol
(nmol.L"')
FP 0.13*0.09 0.14± 0.05 0.15± 0.04 0.16± 0.07
LP 0.25±0.11* 0.34± 0.12* 0.31 ± 0.10* 0.35± 0.11*
Progesterone
(nmol.L"')
FP 1.3 ± 0 . 5 2.2 ± 1 . 1 2.3 ± 1 . 4 1.7 ± 0 . 8
LP 30.1 ± 1 4 . 2 * 29.7± 9.2* 2 6 . 5 ± 9 . 6 * 2 9 . 6 ± 1 0 . 9 *
Data are presented in mean ±SD. An arrow that follows a particular value indicates this vari-
able to be higher (T) or lower ( i ) than the one in the control group in the corresponding phase
of the menstrual cycle. The symbol * indicates the LP value in a particular subgroup to be dif-
ferent from that in the FP.
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and TP subgroups, the luteal natriuresis was lower than that in the FP, most likely
due to less compliance with the diet.
The endocrine data are listed in Table 5. Baseline ANP and norepinephrine were
higher in the HT subgroup then in the control group. With respect to the cyclicity
we noted a luteal rise in the hormones of the renin-angiotensin-aldosterone (RAA)
system and a fall in ANP in all groups except for REST women. Except for the HT
subgroup, in all other groups luteal norepinephrine was found to have increased
relative to the FP. The difference between the luteal and follicular value for the
other neurohormones was inconsistent. Finally, baseline levels and cyclic change
in 17|J-estradiol and progesterone were comparable in all groups.
| DISCUSSION
IB
a
| Endothelial dysfunction plays a central role in the development of PE ' ^ . Endo-
.§• thelial function can be jeopardized either biochemically (i.e. thrombophilia, dia-
E betes mellitus) or mechanically (i.e. hypertension, renovascular disease) '40,153
"I PE seems to be superimposed upon a preexisting disorder and may be the clinical
$ expression of "endothelial decompensation" which represents the common end-
J point of these two different pathophysiologic pathways. We therefore subdivided
.a our group of ex-PE subjects into a TP and HT subgroup, thus separating them
§ from a group of normotensive ex-PE women without thrombophilia (REST).
* Since in healthy females menstrual changes in hemodynamics and renal function
f largely mimic early pregnancy changes and PE often is preceded by hemodynamic
and renal maladaptation, these finding raised the question whether cyclic men-
strual changes in these functions, as seen in healthy women, would be preserved in
the above mentioned ex-PE subgroups. To answer this question, we studied in the
follicular phase and the luteal phase of the menstrual cycle, clotting, metabolic, re-
nal and cardiovascular function in ex-preeclamptic women and controls and com-
pared the data in the various ex-PE subgroups with those found in a reference
group of normal parous controls.
With respect to the general characteristics, the three subgroups were comparable
both with each other and with the control group, except for a higher BMI in the
REST subgroup. In most women in the TP subgroup, thrombophilia was caused
by AFS, protein S deficiency and HHC, an observation in line with reports by
others ***. Comparison of all baseline hemodynamic, renal and endocrine data in
the three ex-PE subgroups relative to the control group indicated that in the HT
subgroup, the higher MAP was paralleled by a higher CO and CI, but a compara-
ble TPR at the expence of a higher LVW. In this group renovascular resistance was
increased and circulating levels of ANP and norepinephrine elevated. It is unlikely
that the higher CI was secondary to the awareness of having hypertension as in
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only 2 of the 10 women in the HT subgroup the diagnosis "hypertension" was
made at the time of the study and the raised blood pressure was seen during both
measurement sessions ' H Most baseline values for central and renal hemodynam-
ics and endocrine status in the TP subgroup resembled those in the control group.
This indicates that the altered endothelial function in response to thrombophilia
does not seem to influence appreciably cardiovascular function. In the REST sub-
group the relative overweight and the lower PV were most conspicious.
With respect to the central and renal hemodynamic cyclicity during the menstrual
cycle, we found a rise in luteal HR, ERPF and PV in the control group. RVR fell
during the LP in this group. These changes were accompanied by activation of the
RAA-system, a rise in plasma norepinephrine and a fall in ANP. These changes are
in agreement with observations by others 12,139,155 ^ d ^re compatible with a state
of vasorelaxation giving rise to volume expansion as a result of activation of the
sympathetic system and the RAA-system with adaptive suppression of ANP.
In contrast to controls, the HT subgroup had higher basal circulating norepineph-
rine levels which did not fluctuate with the menstrual cycle. Otherwise, their cy-
clic changes in renal and endocrine variables were comparable to those in controls.
In the normotensive ex-PE subgroups renal hemodynamics did not change signifi-
cantly with the menstrual cycle. Hormonal and plasma volume changes, however,
were similar as in controls. These observations indicate that most hemodynamic,
renal and neuroendocrine changes with the menstrual cycle are preserved in ex-PE
individuals.
Although it is known, that in the early stages of essential hypertension PV is re-
duced "*•, we did not find such an abnormality in our hypertensive ex-PE patients
but we did observe a reduced PV in the REST subgroup of ex-PE patients. The lat-
ter, therefore, suggests a condition of'borderline hypertension' in these patients.
The lower PV could then be viewed upon as a compensatory mechanism to mini-
mize a rise in pressure. Why PV is not reduced in the HT subgroup, is less easy to
explain. Perhaps this group already has more advanced renal lesions which inter-
fere with volume control.
In summary, although baseline hemodynamics and volume status differed be-
tween ex-PE subgroups and controls, the cyclicity with the menstrual cycle in the
diree subgroups of ex-PE women, was preserved.
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Q CHAPTER
-^ General discussion
Epidemiological studies suggest a multifactorial pathogenesis of preeclampsia ' ^ .
Besides immune maladaptation and genetic predisposition, various vascular fac-
tors have been identified that enhance the development of preeclampsia. Irrespec-
tive of its primary cause, however, there is general agreement that the first
demonstrable abnormality in preeclamptic pregnancy is defective throphoblast in-
vasion giving rise to poor placentation 32,157 Subsequently, the malfunctioning
placenta may cause intra-uterine growth retardation (IUGR) in the second half of
pregnancy. In some women the clinical expression of poor placentation is
preeclampsia rather than IUGR. The mechanism by which the poorly developed
placenta triggers preeclampsia is still unsettled. It has been suggested that the mal-
functioning placenta releases some "factor X" which leads to endothelial dysfunc-
tion and with it, most of the symptoms of preeclampsia ^ . However, convincing
experimental proof for this concept is lacking. In the present thesis we set out to
study hemodynamic and volume regulating factors as a possible cause of
preeclampsia.
Several years ago, we observed already that in the 5 week of supposedly normal
pregnancy cardiac output (CO) rises, which is associated with a fall in blood pres-
sure and hemodilution ' '^. These changes are consistent with maternal systemic
vasorelaxation and relative hypovolemia and are followed by a steady increase in
the ultrasonic dimensions of the left atrium and inferior vena cava . These ob-
servations led us to postulate the following sequence of events in normal human
pregnancy. Within two weeks after implantation, some still unknown pregnancy-
specific mechanism induces maternal systemic vasorelaxation giving rise to a
high-flow/low-resistence circulation. The extra blood volume needed to maintain
such a circulation for a prolonged period of time is met by enhanced volume reten-
tion '58.
Some of the seemingly healthy participants in our study developed IUGR and/or
preeclampsia later on in their pregnancy. Further analysis revealed that, at the start
of the study in early pregnancy, these seemingly healthy subjects had smaller cen-
tral cardiovascular dimensions as compared to the subjects with uneventful preg-
nancy "^. In addition, they failed to respond to pregnancy with systemic
vasorelaxation and plasma volume (PV) expansion. The sequence of events in
these pregnancies may thus be as follows. A preexisting subnormal filling of the
vascular bed is related to enhanced vasoconstriction in these women. Any vasore-
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laxing stimulus from pregnancy must now be offset by enhanced sympathetic
stimulation and activation of the RAA-system as long as these women are unable
to provide adequate filling of their vasculature. In this respect, the recently ob-
served state of sympathetic overactivity in preeclamptics is consistent with this
concept '3*. The proposed hemodynamic maladaptation in early pregnancy may
interfere with the decidual perfusion at the implantation site causing deficient tro-
phoblast invasion and with it defective placental development.
In recent years various research groups have studied hemodynamic patterns dur-
ing the menstrual cycle. The results were conflicting although there was indirect
evidence for mild vasorelaxation in the luteal phase resembling that in early preg-
nancy ^'". These observations formed the basis for the set of studies in the present
thesis. The overall hypothesis we intended to test was:
To test this hypothesis we first studied hemodynamic and volume regulatory
cyclicity in healthy nulliparous women (chapter 3, 4 and 5), to obtain reference
values. We also tried to determine the individual contribution of 17(3-estradiol
and progesterone to the observed cyclic changes in hemodynamics and volume
homeostasis (chapter 6). Finally, we studied hemodynamics, renal function and
body fluid volumes under basal conditions (chapter 7) and during the menstrual
cycle (chapter 8) in women with a history of preeclampsia.
In a pilot study '^ in nine women with an ovulatory menstrual cycle, we could not
substantiate the finding of generalized vasorelaxation during the LP of the men-
strual cycle. In that study we employed non-invasive techniques to measure ve-
nous and arterial tone, glomerular filiation rate (GFR) and blood flows to skin,
forearm and kidneys. Luteal skin blood flow was consistently lower and luteal
GFR higher than values obtained in the FP. However, none of the other variables
changed with the menstrual cycle. The observed luteal fall in arteriovenous shunt
flow to the skin was considered functional as it raises core temperature, a response
which can be expected in conjunction with the well-known progesterone-
dependent upward resetting of the thermoregulatory center. The 10% higher
GFR together with a trend towards a lower renal vascular resistance (RVR) in the
LP suggest postovulatory renal vasodilation. Because of the small population sam-
ple and the large measurement error for most of the variables studied, the power of
this study was modest. However, renal hemodynamics are influenced by dietary
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sodium, a factor which was not controlled for in the present study. We also
thought that information on cardiac output and body fluid volumes could be nec-
essary to describe (systemic) vascular changes with the menstrual cycle. It follows
that the results of our pilot study were inadequate to accept or reject our initial hy-
pothesis on the occurrence of systemic vasorelaxation in the LP of the menstrual
cycle.
Thus, we decided to perform a similar study in a larger population with the par-
ticipating subjects using a standardized sodium intake at the time of study. This
time we measured CO, PV, extracellular fluid volume (ECFV) and the circulating
levels of hormones involved in volume regulation. We calculated both for the FP
and the LP, total peripheral vascular resistance (TPR), RVR and forearm vascular
resistance (FVR). Because of the effect of salt intake on the latter variables, we per-
formed our measurements in two consecutive menstrual cycles with the subjects
using in random order, a low- and a high-salt diet. In spite of a regular menstrual
cycle (29 ± 3 days) in all subjects enrolled, only 61% and 44% of the high-salt and
low-salt menstrual cycles, respectively, were ovulatory according to our criterium
of a mid-luteal circulating serum progesterone level above 15 nmol/1. We do not
have an explanation for these relatively low percentages, except chance. In our pi-
lot study 90% of the menstrual cycles were ovulatory.
Salt intake clearly modified hemodynamic and volume regulatory changes with
the menstrual cycle (Chapter 4 and 5), as consistent changes were only observed
during high-salt diet. On a low-salt diet the cyclicity in the measured variables was
abolished. Compliance with the diet was satisfactory as during high-salt diet, rela-
tive to low-salt diet, baseline values of body weight, ECFV and plasma concentra-
tion of atrial natriuretic peptide (ANP) were higher while RAA-system activity
decreased. The hemodynamic, renal and fluid volume changes with the menstrual
cycle during a high-salt diet consisted of a lower luteal TPR, filtration fraction
(FF) and RVR and a higher luteal effective renal plama flow (ERPF) and GFR.
Changes in FVR, ECFV and PV were inconsistent. The changes in volume regula-
tory hormones with the menstrual cycle during high-salt intake consisted of a
higher luteal RAA-system activity together with a trend towards a lower luteal
ANP. Part of these findings have recently been confirmed by another group "".
The results of our study can be summarized as follows. The pattern of hemody-
namic changes in the LP of the menstrual cycle consists of a mild systemic vasore-
laxation, which is also demonstrable in the kidney, and with the amplitude
increasing as a function of salt intake. The endocrine changes in the LP suggest ac-
tivated sodium retention, but the lack of an increase in PV indicates that this is not
very pronounced. The disappearance of hemodynamic/renal cyclicity during
low-salt intake is interesting. It suggests that a certain amount of salt intake is
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needed for the vasculature to relax in the LP. In other words, vasorelaxation can
occur only in the face of a sufficiently expanded ECFV. The hemodynamic, renal
and volume regulatory changes in LP differed from those in early pregnancy by a
lack of increase in skin blood flow, muscle blood flow and PV. Moreover, hemodi-
lution was not observed. In addition, renal vasodilation in the LP was less pro-
nounced and the luteal rise in RAA-system activity and fall in TPR were small
when compared with changes of tliese variables in early pregnancy. By extrapolat-
ing these findings to early pregnancy, one could speculate about the need for suffi-
cient sodium intake, particularly during this period of hemodynamic adaptation.
In this light, the advice to restrict salt intake would do more harm than good.
The relatively high percentage of anovulatory cycles allowed us to compare these
cycles with ovulatory cycles, thus providing some insight in the individual roles of
progesterone and 17fi-estradiol in the hemodynamic changes during the men-
strual cycle (Chapter 6). In view of the above, only high-salt menstrual cycles were
included in this analysis. The luteal rise in serum 17|3-estradiol was comparable in
anovulatory and ovulatory cycles. By definition, the luteal rise in serum progester-
one was much larger in the ovulatory cycles. The cyclic change in TPR, GFR,
RAA-system activity and ANP were comparable in both types of cycles, suggesting
a primary role for 17(3-estradiol in these changes. On the other hand, only in ovu-
latory cycles we found a luteal increase in ERPF in concert with a fall in FF. The
latter supports the view that progesterone induces selective relaxation of the effer-
ent renal arterioles, an observation in line with previous pharmacological studies
by others ' ^ . It follows that the well-known natriuretic effect of progesterone may
be accomplished not only by its affinity for the aldosterone receptor, but also by
reducing the FF ' ^ . In this concept, a lower FF would lead to a lower peritubular
oncotic pressure, which can be expected to reduce proximal tubular sodium and
water reabsorption ' ^ . There is some indirect evidence from an in-vitro study that
progesterone may induce selective vasodilation of the efferent renal arterioles by
down-regulation of ATI receptors in these vessels ' ^ . However, the exploration
of the underlying mechanism of this particular progesterone effect, requires fur-
ther investigation.
The results of our studies into the menstrual cycle of healthy women can now be
summarized as follows. The LP of the menstrual cycle is characterized by mild
salt-dependent vasodilation in the kidney. This effect is paralleled by a higher
RAA-system activity and lower circulating levels of ANP, but without an apprecia-
ble change in PV and ECFV. It follows that changes in these fluid compartments
are small. The observed cyclic changes may be triggered by 17(3-estradiol-
mediated mild generalized vasorelaxation and progesterone-mediated selective
vasodilation of the efferent arterioles in the kidneys. At first sight, these changes
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resemble those in early pregnancy. However, the spectrum of changes in early
pregnancy is much wider and their magnitude much greater than those in the LP.
Therefore, the luteal change in hemodynamics difFers from that in early pregnancy
in a quantitative way.
Apparently, healthy women with a history of preeclampsia and/or IUGR have an
increased risk to develop preeclampsia in a subsequent pregnancy "*°. In these
women, the prevalence of latent abnormalities in e.g. clotting function, metabo-
lism and the immune system is much higher than in a reference group of normal
parous controls ^ . Since hypertension is also preceded by a long latent period with
subtle abnormalities in renal hemodynamics and the RAA-system ' ^ , we decided
to determine whether basal hemodynamics in the FP and hemodynamic changes
with the menstrual cycle in women with a recent history of preeclampsia differ
from those in parous women with a history of only uneventful pregnancies (chap-
ter 7). In this particular study we tested the hypothesis that asymptomatic and
seemingly healthy women with a history of pre-eclampsia do have abnormalities in
their renal hemodynamics and volume status. Although RAA-system activity in
ex-preeclamptics did not differ from that in controls, ERPF was lower, and FF and
RVR were higher in ex-preeclamptics than in controls. The worwoftw/'w sub-
group of ex-preeclamptics had a 10% lower PV, and a more than 50 % lower ANP
as compared to controls. These findings support the hypothesis that also seem-
ingly healthy women with a history of preeclampsia have abnormalities in their
volume status and renal hemodynamics. If these changes would already be present
prior to a pregnancy complicated by preeclampsia, it is tempting to speculate that
there is a particular subgroup of seemingly healthy women with some (sub)clinical
vascular disease that has relative hypovolemia as common denominator.
Finally, we compared the fluctuations in hemodynamic, renal and volume regula-
tory functions with the menstrual cycle in ex-preeclamptics with those in normal
parous controls (Chapter 8). Seemingly healthy ex-preeclamptics were more obese
and had a lower basal PV than parous controls. Meanwhile, the cyclicity in all vari-
ables studied, including PV, did not differ between the ex-preeclamptics and con-
trols. In this study, luteal PV was higher than follicular PV in both the
ex-preeclamptics and the controls. In our previous study PV did not vary with the
menstrual cycle in the approx. 10 years younger nulliparous participants. Possibly,
a higher age and/or multiparity increase the amplitude of the cyclic fluctuations in
PV to above detection level. This stresses the importance of adequate matching for
parity, age and salt intake in this type of studies.
In conclusion, in both healthy and ex-preeclamptic women, hemodynamic, renal
and volume regulatory functions do vary with the menstrual cycle, provided an
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adequate amount of salt is consumed. As compared to early pregnancy, the
number of variables that change in the LP is much smaller, and the magnitude of
the observed changes is always modest, often barely above detection level. There-
fore, we reject our overall hypothesis that maladaptation in early pregnancy is re-
flected in abnormal hemodynamic and volume regulatory changes with the
menstrual cycle. 17|i-estradioi and progesterone act in concert to induce the ob-
served changes with the menstrual cycle. The magnified changes in early preg-
nancy are probably dependent on the presence of an additional pregnancy-specific
vasorelaxing factor. On the other hand basal hemodynamic, renal or volume regu-
latory variables may differ between ex-preeclamptics and controls. Seemingly
healthy ex-preeclamptics without latent disorders such as thrombophilia, the anti-
phospholipid syndrome or hyperhomocysteinemia, are more obese and tend to
have a reduced PV. It is possible that a reduced PV in women at risk for
preeclampsia initiates the cascade of events that leads to poor placentation. On the
other hand, it is also conceivable that the reduced PV is only a confounder of some
other latent hemodynamic disorder. Hemodynamics and volume regulation in
early pregnancy rather than during the menstrual cycle, should be subject to future
§ study. The objectives of such prospective studies should be to explore the mecha-
| nism responsible for the early-pregnancy vasorelaxation, and to assess to what ex-
|6 tent the hypovolemic state in ex-preeclamptics contributes to the pathogenesis of
5 preeclampsia.
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Generalized vascular relaxation in the early first trimester can be seen as an impor-
tant physiologic hallmark of an uncomplicated pregnancy. In contrast, pregnan-
cies complicated by preeclampsia and/or fetal growth restriction are preceded by
abnormal hemodynamic adaptation in early pregnancy. The objective of this the-
sis was to investigate whether in preeclamptic pregnancy maladaptation in central
and renal hemodynamics in early pregnancy is mirrored by abnormal hemody-
namic changes during the menstrual cycle. In the first part we investigated
whether the menstrual cycle mimics the hemodynamic changes of early preg-
nancy. The second part dealt with the question whether the cyclic hemodynamic
changes in women with a history of preeclampsia are different from those observed
in women with a history of uneventful pregnancies.
Chapter 2 is a review of the literature in regard to the pathogenesis of preeclamp-
sia. Placental ischemia secondary to defective placentation, a prerequisite for the
development of preeclampsia, has a multifactorial origin consisting of three major
components: immune maladaptation, genetic predisposition and vascular medi-
ated factors. Probably, a summation of these factors will determine whether or not
a pregnant woman is to develop die syndrome.
Chapter 3 describes a pilot-study in which we investigated whether the luteal
phase of the menstrual cycle differs from the follicular phase by the development
of a state of general vascular relaxation. The results did not support the concept of
a luteal state of general vascular relaxation. We could not demonstrate a statisti-
cally significant increase in blood flow to the investigated vascular beds (skin, fore-
arm and kidneys) during the luteal phase of the menstrual cycle.
The study in Chapter 4 was designed to investigate whether total peripheral vascu-
lar resistance decreases and plasma volume and extracellular fluid volume increase
in the luteal phase of the menstrual cycle relative to the follicular phase. Despite
the activation of sodium and fluid retaining mechanisms, extracellular fluid vol-
ume and plasma volume did not increase appreciably in the luteal phase of the
menstrual cycle. Apparently, the stimulus of arterial relaxation, and subsequent ar-
terial underfill, in the luteal phase of the menstrual cycle is, compared to early
pregnancy, too weak to elicit a measurable rise in extracellular fluid volume and
plasma volume.
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In Chapter 5 we evaluated total peripheral resistance, renal vascular resistance,
glomerular filtration rate and forearm vascular resistance in the menstrual cycle
during low- and high-salt diet. The data showed, in case of sufficient salt intake, a
decrease in both total peripheral resistance and renal vascular resistance without
concomitant consistent changes in forearm vascular resistance in the luteal phase
of the menstrual cycle. The increase in glomerular filtration rate in the luteal phase
is paralleled by an increase in effective renal plasma flow and a decrease in filtration
fraction. Post-ovulatory vasodilation of efferent, more than afferent, renal arteri-
oles could be responsible for the raised glomerular filtration rate. The hemody-
namic changes induced by the endocrine environment of the luteal phase of the
menstrual cycle were modified by salt intake, and mimic the hemodynamic adap-
tation to early pregnancy.
In Chapter 6 we investigated the relative contribution of endogenous progester-
one and 17(5-estradiol to the above described hemodynamic changes during the
menstrual cycle by comparing ovulatory - with anovulatory cycles. Except for a
difference in cyclic change in serum progesterone, effective renal plasma flow, fil-
tration fraction and renal fraction, we did not find a statistically significant differ-
ence in cyclic hemodynamic changes between ovulatory and anovulatory
|" menstrual cycles. Although in many instances both steroids may act in concert in
| inducing the hemodynamic changes with the menstrual cycle, the results of this
*" study suggest that the luteal fall in total peripheral resistance and rise in glomerular
— filtration rate are primarily mediated by 17P-estradiol, whereas, the luteal rise in
fc effective renal plasma flow seems to be primarily a progesterone-dependent effect.
In Chapter 7 we tested the hypothesis that women with a recent history of
preeclampsia have abnormalities in their renal hemodynamics and volume status.
We observed that women with previous preeclampsia are relatively hypovolemic
and tend to have a lower effective renal plasma flow and a higher renal vascular re-
sistance and filtration fraction as compared to controls. These findings support
the hypothesis that "healthy" women with a history of preeclampsia show abnor-
malities in their volume status and renal hemodynamics, irrespective of their
blood pressure.
In Chapter 8 we compared cyclic change in volume status and renal hemodynam-
ics in women with a recent history of preeclampsia with that in controls. There
were no differences observed in cyclic change between ex-preeclamptics and con-
trols. We only observed differences in baseline values in the subgroups of ex-
preeclamptics with hypertension and apparently healthy ex-preeclamptics as
specified in Chapter 7.
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In conclusion, the data presented in this thesis show that hemodynamic changes in
the LP of the menstrual cycle resemble those in early pregnancy, and also that
these adaptations are dependent upon salt intake. If salt intake is sufficient, a mod-
est general vascular relaxation is observed in the LP of die menstrual cycle. The as-
sociated lower luteal TPR seems to be primarily mediated by 17(3-estradiol.
Although, sodium and fluid retaining mechanisms are activated, PV and ECFV
do not increase appreciably in the LP. The luteal increase in ERPF exceeds that in
GFR thus giving rise to a lower FF. The results of our study in anovulatory cycles
provides indirect evidence for the concept that the higher ERPF and lower FF in
the LP of the menstrual cycle are primarily progesterone-dependent and secondary
to selective relaxation of die efferent renal arterioles.
The second part of this thesis demonstrates diat, based on our findings of a re-
duced PV and suppressed level of ANP, women with a history of preeclampsia are
relatively hypovolemic. Possibly, a decreased circulatory volume may have caused
the observed lower renal blood flow and higher FF. Hemodynamic adaptation
during the menstrual cycle in ex-preeclamptics is comparable to that observed in
women with a history of uneventful pregnancies. To what extent the hypovolemic
state in ex-preeclamptics contributes to the pathogenesis of preeclampsia is the ob-
jective of future studies.
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Samenvatting
Een belangrijk fysiologisch verschijnsel van een ongestoord verlopende zwanger-
schap is het optreden van een gegeneraliseerde vasodilatatie vroeg in het eerste tri-
mester. In zwangerschappen, die gecompliceerd raken door preeclampsie en/of
foetale groeiretardatie, verlopen deze vroege aanpassingen in de bloedsomloop
echter arwijkend. Het doel van dit proefschrift was ora te onderzoeken of deze
vroeg optredende maladaptatie in een door preeclampsie gecompliceerde zwan-
gerschap weerspiegeld wordt door afwijkende hemodynamische veranderingen
tijdens de menstruele cyclus. In het eerste gedeelte van dit proefschrift hebben wij
onderzocht of de hemodynamische veranderingen van de vroege zwangerschap
worden nagebootst in de menstruele cyclus. Het tweede gedeelte behandelt de
vraag of hemodynamische veranderingen in de menstruele cyclus bij vrouwen met
een preeclampsie in de anamnese vergelijkbaar zijn met die bij vrouwen met een
bianco anamnese.
^, Hoofdstuk 2 behandelt de literatuur met betrekking tot de pathogenese van
I preeclampsie. Een gestoorde placentatie met als gevolg placentaire ischemie lijkt
^ een voorwaarde voor het ontstaan van preeclampsie. Deze gestoorde placentatie is
• vaak multicausaal, waarbij er drie categorieen van afwijkingen te onderscheiden
1 zijn, te weten: een afwijkende aanpassing van het afweersysteem, genetische aanleg
g- en vasculair gemedieerde factoren. Waarschijnlijk bepaalt een optelsom van deze
*-" factoren of een zwangere vrouw preeclampsie zal ontwikkelen.
Hoofdstuk 3 beschrijft een pilot-studie bij gezonde vrouwen waarbij we de hypo-
these getoetst hebben, dat er in de luteale fase van de menstruele cyclus in vergelij-
king tot de folliculaire fase een gegeneraliseerde vasodilatatie optreedt. We zagen
in de luteale fase van de cyclus geen significante toename in de doorbloeding van
de huid, skeletspier (onderarm) en de nieren. Deze onderzoeksresultaten boden
geen ondersteuning voor de geponeerde hypothese. Daarbij dient wel de kantteke-
ning geplaatst te worden, dat de power van de pilot-studie laag was.
De studie in hoofdstuk 4 was ontwikkeld om te onderzoeken of, in vergelijking
tot de folliculaire fase, de totale perifere vaarweerstand zou afnemen en het plas-
mavolume en extra-cellulaire volume zou toenemen in de luteale fase van de men-
struele cyclus bij gezonde vrouwen. Ondanks de activatie van zout- en
vochtretinerende mechanismen nam het extra-cellulaire volume en plasmavolume
niet toe in de luteale fase van de menstruele cyclus. Blijkbaar was de stimulus van
arteriele relaxatie, met als gevolg arteriele ondervulling in de luteale fase van de
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menstruele cyclus, te zwak in vergelijking tot die in de zwangerschap, om een
meetbare toename te veroorzaken in het extra-cellulaire volume en plasmavolume.
In hoofdstuk 5 hebben wij de totale perifere vaatweerstand, renale vaatweerstand,
glomerulaire filtratiesnelheid en vaatweerstand in de onderarm onderzocht tijdens
de menstruele cyclus bij gezonde vrouwen die achtereenvolgens een laag - en hoog-
zout dieet gebruikten. Alleen bij een hoogzout dieet tijdens de luteale fase van de
menstruele cyclus konden wij een afname van de totale perifere vaatweerstand en
renale vaatweerstand aantonen met een gelijkblijven van de vaatweerstand in de
onderarm. De toename van de glomerulaire filtratiesnelheid ging vergezeld van
een toename van de effectieve renale plasma doorstroming en een afname in de fil-
tratie fractie. De luteale toename in glomerulaire filtratiesnelheid zou een gevolg
kunnen zijn van een sterkere vaatverwijding van de efferente renale arteriolen, die
vanuit de glomerulus de peritubulaire microcirculatie verzorgen, dan van de affe-
rente renale arteriolen naar de glomerulus toe. De luteale veranderingen in bloeds-
omloop bleken afhankelijk te zijn van de zoutconsumptie en tonen
overeenstemming met het patroon van hemodynamische veranderingen, die men
in de vroege zwangerschap ziet.
In hoofdstuk 6 werd de relatieve bijdrage van endogeen progesteron en
17P-oestradiol aan de bovengenoemde veranderingen in de bloedsomloop tijdens
de menstruele cyclus bestudeerd door ovulatoire met anovulatoire cycli te vergelij-
ken. De cyclische veranderingen in ovulatoire en anovulatoire cycli waren voor
bijna alle gemeten variabelen vergelijkbaar, met uitzondering van de mate van toe-
name in het serum progesteron, de effectieve renale plasma doorstroming, de fil-
tratie fractie en de renale fractie van het hartminuutvolume. Hoewel meestal beide
steroi'den samenwerken bij het veroorzaken van hemodynamische veranderingen
tijdens de menstruele cyclus, suggereren deze resultaten dat de luteale afname in
totale perifere vaatweerstand en toename in glomerulaire filtratiesnelheid voorna-
melijk veroorzaakt worden door 17(3-oestradiol. De luteale toename in effectieve
renale plasma doorstroming lijkt voornamelijk veroorzaakt te worden door pro-
gesteron.
In hoofdstuk 7 hebben wij de hypothese getoetst, dat vrouwen met preeclampsie
in de voorgeschiedenis afwijkingen vertonen in renale hemodynamiek en plasma-
volume. Wij konden aantonen dat vrouwen met preeclampsie in de voorgeschie-
denis in vergelijking tot vrouwen met een bianco voorgeschiedenis een verlaagd
plasmavolume hebben, vaak gepaard gaand met een lagere effectieve renale plasma
doorstroming enerzijds, en een hogere renale vaatweerstand en filtratie fractie an-
derzijds. Deze bevindingen ondersteunen de hypothese, dat ogenschijnlijk gezon-
de vrouwen, die in het verleden een preeclampsie hebben doorgemaakt, een
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verlaagd plasmavolume hebben vaak in combinatie met een licht gecompromit-
teerde renale hemodynamiek.
In hoofdstuk 8 hebben we cydische veranderingen in plasmavolume en renale he-
modynamiek bestudeerd in een groep vrouwen met preeclampsie in de voorge-
schiedenis en deze vergeleken met een groep vrouwen, die een ongestoorde
zwangerschap hadden doorgemaakt. Alhoewel de vrouwen zowel een lager plas-
mavolume hadden alsook een licht verlaagde renale hemodynamiek (zie hoofd-
stuk 7), waren alle cyclische veranderingen tussen de groepen vergelijkbaar.
Concluderend kunnen we stellen, dat met de data in dit proefschrift wordt aange-
toond dat de hemodynamische veranderingen in de luteale fase van de menstruele
cyclus Iijken op die in de vroege zwangerschap, met als bijzonderheid, dat de am-
plitudo van de cyclische veranderingen toeneemt naarmate er meer zout geconsu-
meerd wordt. Bij voldoende zout inname wordt er een bescheiden
j? gegeneraliseerde vasodilatatie waargenomen in de luteale fase van de menstruele
' j cyclus. De lagere totale perifere vaatweerstand in de luteale fase lijkt voornamelijk
1 veroorzaakt door het 17(i-oestradiol. Alhoewel zout- en vochtretinerende mecha-
5 nismen zijn geactiveerd, nemen plasmavolume en extra-cellulair volume niet toe
i in de luteale fase. De luteale toename van de effectieve renale plasma doorstro-ming is groter dan die van de glomerulaire filtratiesnelheid, waardoor de filtratiefractie daalt. Onze bevindingen in de studie van anovulatoire cycli ondersteunen
;; de idee, dat de hogere effectieve renale plasma doorstroming en lagere filtratie frac-
f tie in de luteale fase van de menstruele cyclus voornamelijk effecten van progeste-^ ron zijn, hetgeen mogelijk tot stand komt door een selectieve relaxatie van
efferente renale arteriolen.
Het tweede deel van dit proefschrift toont aan dat, gebaseerd op onze bevindingen
van een verlaagd plasmavolume en ANP, de vullingsgraad van het vaatbed bij
vrouwen met preeclampsie in de voorgeschiedenis krapper is. Mogelijk dat een
verlaagd circulerend volume de oorzaak is van de waargenomen lagere nierdoor-
bloeding en hogere filtratie fractie. De hemodynamische veranderingen tijdens de
menstruele cyclus bij vrouwen met preeclampsie in de voorgeschiedenis zijn verge-
lijkbaar met die bij vrouwen met een bianco voorgeschiedenis. In hoeverre de ver-
minderde vullingsgraad bij vrouwen met preeclampsie in de voorgeschiedenis een
rol speelt in de pathogenese van preeclampsie is het doel van toekomstige studies.
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Nawoord
Bij de totstandkoming van dit proefschrift zijn in de loop der jaren veel mensen op
enigerlei wijze betrokken geraakt. Zonder hun hulp zou her mij beslist niet gelukt
zijn dit proefschrift te schrijven. Ik zou dan ook alien graag willen bedanken mid-
dels het promotiefeest.
Toch wil ik enkelen speciaal noemen zonder hiermee anderen te kort te willen
doen.
Liefste Margreet, door jouw onvoorwaardelijke steun en kritische blik tijdens deze
zeven jaren van opleiding en onderzoek, ook op de momenten dat het war minder
ging, heb ik beide tot een goed einde kunnen brengen. Daarom heb ik dit proef-
schrift aan jou opgedragen, wetende dat het nooit was verschenen zonder jouw
steun. Daarnaast stond jij altijd klaar voor onze kinderen en wist je dit te combine-
ren met het huisartsenvak. Ik heb de grootste bewondering voor jou.
Beste Louis, door jouw creatieve geest en inzet is deze onderzoekslijn en ook dit
proefschrift voor een belangrijk deel tot stand gekomen. Alhoewel, of misschien
welyWrt owditt mijn enigszins calvinistische inslag niet altijd spoorde met jouw
meer Zuidelijke kijk op de gang van zaken, wat betreft interpretatie van het onder-
zoek en de organisatie van de onderzoekslijn, is onze samenwerking heel vrucht-
baar geweest.
Beste Peter, door jouw nuchtere wetenschappelijke analyses en grote nefrologische
kennis heb je ons menigmaal behoed voor al te wilde speculaties. Veel dank voor je
begeleiding.
Beste professor de Haan, zowel opleider als promotor, ongetwijfeld heeft u,
naast Hans Brolmann, grote invloed gehad op mijn vorming tot gynaeco-
loog. Mede uw stimulering om wetenschappelijk onderzoek te doen naast de
opleiding tot gynaecoloog is van belang geweest bij het tot stand komen van
dit proefschrift. Met name de inpassing van het onderzoeksproject binnen
mijn opleidingsschema werd door u gesteund en georganiseerd.
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